We are IntechOpen,
the world's leading publisher of
Open Access books
Built by scientists, for scientists

4,800
Open access books available

122,000
International authors and editors

135M
Downloads

Our authors are among the

154
Countries delivered to

TOP 1%
most cited scientists

12.2%
Contributors from top 500 universities

BOOK CITATION INDEX
CLARIVATE ANALYTICS
INDEXED

WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com

Traveller's Diarrhoea and Intestinal Protozoal Diarrhoeal Disease

Constantine M. Vassalos and Evdokia Vassalou
National School of Public Health, Athens
Greece

1. Introduction

Traveller's diarrhoea is usually a mild gastrointestinal disorder. It is generally acute and short-term, but in 10 percent of all cases symptoms last for more than a week. Bacterial and viral agents are responsible for more than 80 percent of cases of acute traveller's diarrhoea. Though incriminated in only one to three percent of cases of acute traveller's diarrhoea, parasites –mainly protozoa– account for about 30 percent of cases of persistent diarrhoea in travellers (Leder, 2009; Okhuysen, 2001). Recent acceleration and expansion of international travel for business, leisure, philanthropic or other purposes has contributed to an increase in cases of intestinal protozoal disease in the developed world (Topazian & Bia, 1994; Vassalou & Vassalos et al., 2010).

2. Traveller's diarrhoea

Since the 1950s, a decade which saw an increase in trips to exotic locales, the prospect of developing diarrhoea has been a major concern for foreign travellers. It is believed that traveller's diarrhoea is the most common health problem of people journeying abroad for education, research, business, or pleasure. Traveller's diarrhoea is classically defined as the passage of three or more unformed stools in a 24-hour period with or without mild gastrointestinal symptoms including cramps, nausea and mild fever (Steffen, 2005). More serious gastrointestinal symptoms, such as vomiting and dysentery with blood and/or mucus in the stool, are rare. Owing to the brief incubation period that ranges from hours to a few days, it is most likely that traveller's diarrhoea will develop on the third or fourth day of the travel. A second peak is observed around the 10th day, although some digestive problems may occur at any time (Cailhol & Bouchaud, 2007).

3. Aetiological agents

Many non-infectious phenomena, such as a change in lifestyle, climate or eating habits, consumption of spicy foods, and psychosomatic conditions, have been incriminated as causes of diarrhoea in the traveller. However, traveller's diarrhoea is generally of an infectious origin. Bacteria account for approximately 60 to 80 percent of all cases, whereas viral agents and parasites, mainly protozoa, are responsible for about 10 to 20 percent and 5 to 10 percent of the cases, respectively (Ericsson et al., 2008). There are differences in

causality among travel destinations, depending on the geographical distribution of pathogenic organisms. Enterotoxigenic *Escherichia coli*, or ETEC, is a major bacterial cause of traveller's diarrhoea worldwide. Several other bacteria, for instance *Shigella*, *Campylobacter*, *Salmonella*, *Aeromonas*, *Plesiomonas*, and non-cholera vibrio species, have also been involved (Shah, 2009). Rarely is *Vibrio cholerae* transmitted to western travellers. The risk of contracting cholera is estimated at one per 500,000 travellers to endemic areas (Synder & Blake, 1982). Enterotoxigenic *Bacteroides fragilis*, or ETBF, and *Arcobacter* strains including diarrhoeagenic *A. butzleri* as well as *A. cryaerophilus*, formerly considered non-pathogenic, have recently been shown to cause diarrhoea in those travelling to different parts of the Indian subcontinent and Latin America (Houf & Stephan, 2007; Jiang et al., 2010). In cruise ships and tourist resorts, there is high risk of acquiring viruses such as noroviruses (Domènech-Sánchez et al., 2009; Koo et al., 1996). Rotavirus, a common paediatric pathogen, has also been found in adults with traveller's diarrhoea (Anderson & Weber, 2004). *Giardia* is the most commonly encountered parasite among travellers with diarrhoea. *Cryptosporidium, Cyclospora, Isospora,* and microsporidia are emerging causes (Goodgame et al., 2005). Aetiological agents and their order of occurrence by different geographical regions are shown in Table 1.

Aetiological agents	Africa	Latin America	South Asia	Southeast Asia
Enterotoxigenic *Escherichia coli*	1	1	1	5
Enteroaggregative *E. coli*		2	2	
Enteropathogenic *E coli*	4	4		2
Campylobacter			4	1
Salmonella			5	3
Shigella	3		3	
Non-cholera vibrios				4
Norovirus	2	3		
Rotavirus	5	5		

Table 1. Traveller's diarrhoea: aetiological agents and their order of occurrence (from 1 to 5) among different geographical regions (adapted from Shah et al., 2009).

3.1 Pathogenicity

A variety of pathogens have been shown to contribute to traveller's diarrhoea. Based on the pathophysiological mechanism responsible for the diarrhoea, their pathogenicity can be divided into non-inflammatory, enteroinvasive, and inflammatory types. However, irrespective of the mechanism involved, the host defence system is evaded and modulated. Concerning traveller's diarrhoea of bacterial origin, the non-inflammatory diarrhoeas are due to enterotoxin-producing organisms, such as *Vibrio cholerae* and ETEC, which adhere to the mucosa and disrupt the absorptive and secretory functions of the enterocyte. In the case of viral traveller's diarrhoea, viruses such as rotaviruses disrupt the digestive and absorptive functions of the enterocyte: therefore the diarrhoea caused by the rotavirus is classified as osmotic. Enteroinvasive organisms such as *Salmonella*, *Shigella*, *Campylobacter*, or *Entamoeba histolytica* produce diarrhoea by invading intestinal mucosal barriers, followed by the initiation of acute inflammatory reaction through activation of cytokines and other

Localization	Enteropathogens	Virulence factors	Mechanisms
Small bowel	Enterotoxinogenic *E.coli* (ETEC)	Colonization factors (CFs) (adherence) Heat-labile toxin (LT), Heat-stable toxin (ST) (toxins)	Secretory (toxinogenic)
	Enteroaggregative *E.coli* (EAEC)	AAFs, dispersin (adherence) EAST1, Pet, Pic, ShET1 (toxins)	
	Vibrio cholerae	ACF, TCP (adherence) Ace, CT, RTX toxin, Zot (toxins)	
	Vibrio parahaemolyticus	Vp-TDH, Vp-TRH, Vp-TDH/1 (haemolysins)	
	Rotavirus	VP4 (adherence) NSP4 (toxin)	Osmotic Apoptosis of enterocytes
	Norovirus	VP1-P2 domain (adherence)	Absorptive villus
	Giardia spp.	Variant-specific surface proteins (VSPs), arginine deiminase	Architecture disruption
	Cryptosporidium spp.	Unknown	
	Cyclospora	Unknown	
Large bowel	*Entamoeba histolytica*	Gal-specific adhesin , cysteine proteinases, amoebapores Gal/GalNAc lectin, amoebapore and cystein proteases	Invasive
Small bowel and large bowel ileocolonic	*Campylobacter* spp.	CadF, JlpA, LOS, MOMP, PEB1 capsule (adherence) CiaB (invasion) CDT (toxin)	Inflammatory Invasive
	Shigella spp.	IcP, (SopA), Pic, SigA (protease) ShET1, ShET2, Shiga toxin (*S. dysenteriae*) (serotype 1 only) (toxin)	
	Salmonella spp.	AgF, LpF, MisL, Pef, RatB, ShdA, SinH, Type 1 fimbriae (adherence) Vi antigen (*S. enterica*) (serovar typhi) (immune evasion) CdtB (*S. enterica*) (serovar typhi), Spv (toxin)	
	Aeromonas hydrophila	Cytotonic Alt [heat-labile] and Ast [heat-stable], cytotoxic Act (enterotoxin) aerolysin (cytotoxin), hyl H (haemolysin).	
	Yersinia enterocolitica	Ail, Invasin (invasion) Yst (toxin)	

Table 2. Traveller's diarrhoea: localization, mechanisms and virulence factors of enteropathogens.

inflammatory mediators. In addition to enteroinvasive organisms, inflammatory diarrhoea can also be caused by cytotoxin-producing non-invasive bacteria, such as EAEC and *Clostridium difficile*, which adhere to the intestinal mucosa, activate cytokines and release inflammatory mediators (Navaneethan and Giannella, 2008).

3.1.1 Virulence factors

All the classical virulence factors including endotoxins, fimbriae and flagella, plasmids, apoptotic inducers, pathogenic islands and complete types I, II, and III secretion systems have been identified as being responsible for traveller's diarrhoea. Virulence factors in strains of *E. coli*, *Shigella*, *Salmonella*, *Vibrio*, *Campylobacter*, *Aeromonas*, *Yersinia*, *E. histolytica*, *Giardia*, and norovirus, as well as genes encoding virulence factors in these enteropathogens have been analysed. These factors are listed in Table 2. Research continues into candidate virulence factors of *Cryptosporidium* spp., while virulence factors of *Cyclospora* are yet to be defined.

4. Epidemiological data

Each year 100 million people from industrialized countries travel to areas of high risk for contracting traveller's diarrhoea, the majority of which are in the developing world. And up to 40 million cases of diarrhoea are reported among such travellers. Approximately 15 to 50 percent of travellers to tropical and subtropical areas in Africa, the Caribbean and Latin America, or in South Asia may develop diarrhoea (Steffen, 2005). Traveller's diarhoea can affect men and women equally. It is rare in travellers over the age of 55, while it is more frequent in children and in young adults under the age of 30 (Pitzinger et al, 1991). A Geosentinel study indicated that in more than 17,000 international travellers acute and chronic diarrhoea were the most common syndromes — at a rate of 335 diarrhoeal cases per 1,000 returned travellers (Freedman et al., 2006). Travellers to South Central Asia are at the greatest risk of contracting acute diarrhoea. On the other hand, the highest rates of chronic diarrhoea were reported after a journey to West Africa and East Asia (Sanders et al., 2008). ETEC is the main causal agent of traveller's diarrhoea in Africa, Latin America, and South Asia, followed by enteroaggregative *E. coli*, or EAEC, in Latin America and South Asia, whereas *Campylobacter* predominates in Southeast Asia (Hill & Beeching, 2010). Of the viral agents, noroviruses were found in mixed infections with bacteria such as ETEC in one-third of diarrhoea cases among those travelling to Latin America (Chapin et al., 2005). Rotaviruses are also frequent causes of traveller's diarrhoea in Mexico and Jamaica (Steffen et al., 1999; Vollet e al., 1979,). Considering parasites, *Giardia* has been mostly found after travel to central parts of South Asia (Freedman et al., 2006). *E. histolytica*, like other parasites, is frequently encountered among travellers returning from Asia, however seldom found after a short stay in Mexico (Frachtman et al., 1982; Freedman et al., 2006). Study groups in Nepal, Haiti and Peru have shown that *Cyclospora* is endemic in the regions of South Asia, the Caribbean and Latin America, respectively (Yates, 2005). In most cases, traveller's diarrhoea is quite mild, benign, and lasts for a short period of time (Hill, 2000). However, in 40 percent of the cases, digestive disturbances may lead to a change in travel plan with a potential for serious negative impact on the travel objective, for instance that of a business traveller. In 20 to 30 percent of cases, travellers may be confined to bed for a period of time, while in some (<1%) hospitalization is required.

5. Sources and modes of transmission

Traveller's diarrhoea is most commonly contracted by ingesting food and/or beverage contaminated with faecal material of human or animal origin. Despite the popular belief that drinking water posed the most significant risk for traveller's diarrhoea, unsafe/contaminated food was shown to be the major vehicle for infection. Raw or rare meat, poultry and seafood, and also the fruit and vegetables eaten raw are the more likely vehicles to spread the pathogens. Direct contact with contaminated, unwashed hands and indirect transmission by non-biting flies, such as the house fly, play only secondary roles in the transmission of diarrhoea to the traveller.

6. Risk factors

There are a variety of environmental and host-related factors that can predispose travellers to diarrhoeal illness. These risk factors include those that are associated with travel destination, planning, or seasonality and those in relation with the traveller's age, eating habits, or susceptibility.

Environment has been considered to have an impact on traveller's diarrhoea. The wider hygiene gap between the country of origin with a higher level and that of the destination may put a traveller at greater risk of contracting traveller's diarrhoea. Travel destinations are classified into three groups according to their hygiene level. Group I includes developed countries such as the United States, Canada, Australia, New Zealand, Japan, and the North and Western European countries with high level of hygiene and consequent low risk for acquiring diarrhoea by travellers to those countries (at a rate less than eight percent). Group II consists of areas of intermediate risk (at a rate of eight to 20 percent): such as Eastern European countries, South Africa, tourist places in Thailand, the Caribbean, and the Mediterranean. Areas of low hygiene level and high risk (at a rate more than 20 percent), such as the most part of Asia, the Middle East, Africa, and Central and South America, belong to group III. Furthermore, individuals travelling to temperate regions in winter are less at risk: for instance, the rate for *Campylobacter* infection was 58 percent in autumn, while it was only eight percent in the wintertime (Mattila et al., 1992). A recent study indicated that the rate for both enteroaggregative and enteropathogenic *Escherichia coli* infections among visitors to Mexico in winter was similar to that recorded in summer, whereas the rate of ETEC traveller's diarrhoea increased by seven percent for each degree centigrade increase in weekly ambient temperature (Paredes-Paredes et al., 2011). In travellers to the Tropics, however, the occurrence of diarrhoea does not seem to follow a clear seasonal pattern: EAEC, *Shigella*, and rotavirus are mostly found during the dry season. And those travelling during the rainy season or post-moonson are at a high risk for acquiring traveller's diarrhoea due to ETEC or *Giardia*, but not viral diarrhoea. (Taylor & Echeverria, 1986). The effect of the El Niño/Southern Oscillation, or ENSO, climate phenomenon should also be considered: the rise in average annual temperatures related with ENSO event has been positively associated with risk of diarrhoeal disease (Lauerman, 2001; Lama et al., 2004; Sari Kovats et al., 2003).

Travel plans and itineraries are also related to the possibility of exposure. Campers and backpackers, people who have more contact with the rural population, are at a higher risk than are business travellers (Piyaphanee et al., 2011). Being busy and often confined to

their hotel rooms, business travellers dine in their hotels. Organized travelling and planned itineraries may be considered safer. However, unforeseen situations may arise (Vassalos & Vassalou et al., 2011). For instance, travellers may end up eating food that has been on display for several hours or may try food from street vendors and local popular restaurants (Tjoa et al.,1977; Adachi, 2002). In the latter case, inadequate water supplies can lead to incorrect dish washing. Improper storage of food may also result from limited access to electricity. Recently, it has been shown that food contamination is widespread in developing countries despite the fact that food is cooked and served hot (Koo et al., 2008). Also, the individual traveller may or may not practise sound eating habits regarding consumption of food and/or water. Travellers visiting areas with access to clean drinking water and food are at lower risk for diarrhoea. In addition to all the foregoing, overcrowded areas such as campgrounds, military camps and cruise ships are particularly prone to diarrhoeal disease.

Besides environmental factors, host-related factors, viz personal factors and host genetic background, may also contribute to traveller's diarrhoea risk. Traveller's diarrhoea usually develops at the beginning of the tour. A longer stay may, however, increase the possibility of the occurrence of a gastrointestinal disorder (Piyaphanee et al., 2011). Young people are the ones most likely to develop diarrhoeal disease because of their keenness to explore the local flavours. Elderly travellers are less liable to contract diarrhoea, since they are more cautious about what they eat and drink (Alon et al., 2010). But they are also more likely to suffer complications because of their immunocompromised status from having debilitating, underlying medical conditions, such as diabetes, renal failure or hypochlorhydria induced by taking antacids. Rehydration therapy is important for the very young, elderly and those in cardiac glycosides or diuretics (DuPont & Khan, 1994). In contrast, healthy travellers visiting areas of low hygienic level may only experience mild gastrointestinal symptoms. The development of natural immunity plays a role in the lower rates of diarrhoeal disease among the locals in destination countries with relatively lower levels of socio-economic development. Similarly, earlier travel to an area of low hygienic level would also reduce the possibility of acquiring traveller's diarrhoea due to the immunity acquired from previous exposure to pathogens prevalent in such areas (DuPont et al., 1986). That is particularly important for travellers with high socio-economic status, who are less likely to develop protective immunity in their countries of origin.

Persons with blood type O are susceptible to developing cholera, whereas individuals with blood type A are more likely to get giardiasis (Harris et al., 2005; El- Ganayni et al., 1994). Differences in ABO, Lewis, secretor phenotypes seem to be associated with differences in susceptibility to infection caused by norovirus strains (Huang et al., 2002; Hutson et al., 2002; Marionneau et al., 2005). Several single nucleotide polymorphisms, or SNPs, have been investigated for possible association with traveller's diarrhoea. It was found that travellers with the T/T genotype in position codon 632 of the lactoferrin gene were more likely to develop traveller's diarrhoea (Mohamed et al., 2007). Polymorphism in the interleukin (IL)-8 promoter appears to be associated with susceptibility to EAEC (Jiang et al., 2003), whereas polymorphism in IL-10 promoter is likely to be associated with traveller's diarrohea due to ETEC (Flores et al., 2008). Osteoprotegerin, or OPG, is an immunoregulatory member of the tumour necrosis factor receptor superfamily. Polymorphism in the OPG gene has been found to be associated with increased susceptibility to traveller's diarrhoea (Mohamed et al., 2009).

7. Diagnostic approach

In a returned traveller with diarrhoea, a history of events is required to be established post-travel; a questionnaire concerning travel destination and conditions, eating habits, antimalarial chemoprophylaxis, onset of symptoms and other matters is suggested. In post-travel febrile diarrhoea, the traveller should be tested for malaria, given that malarial gastrointestinal manifestations are quite common. Once malaria is excluded, further work up should include routine haematological and biochemical testing, transabdominal ultrasound scan, stool culture and microscopy for cells, ova and parasites. For the isolation of *Escherichia coli*, *Campylobacter*, *Salmonella*, *Shigella*, *Aeromonas*, *Plesiomonas*, *Vibrio* and *Yersinia*, standard microbiological procedures are used. ETBF culture is carried out under anaerobic conditions. In the past, an aetiological agent remained unidentified in about 40 percent of such cases. Improved modern techniques have proven helpful in increasing the rate of identification of the cause of diarrhoea (Shah et al., 2009). The possibility of detecting *Shigella*, *Salmonella* or *Campylobacter* has increased substantially by using polymerase-chain-reaction (PCR)-based methods. Molecular techniques are used to detect the heat-labile and the heat-stable toxins of ETEC, aggR gene of EAEC , ipaH and invE genes of EIEC, and the genes of *B. fragilis* toxin of ETBF. To detect noroviruses, immunochromatography and reverse transcriptase PCR are employed. Diagnostic approach of traveller's diarrhoea is demonstrated in Figure 1.

8. Prevention

8.1 Hygiene measures

Traveller's diarrhoea is associated with inadequate sanitation and hygiene in countries being toured. Occurrence of traveller's diarrhoea is also related to the hygienic standards practised at the food preparation level. The challenge is to avoid faecal contamination of food and water. Furthermore, there is a need to minimize the burden of pathogen in the food and/or water just before consumption (Bandres et al., 1988). It has been shown that consumption of cold foods stored at a temperature that allows microorganisms to grow and produce toxins is responsible for small clusters of sickness even in luxury hotels.

The old adage 'boil it, cook it, peel it, or forget it' remains valid at the individual level. A traveller often wants to taste a local cuisine or to try vendor food, or a traveller may be forced to consume water of suspect quality. Table 3 shows a list of some foods and beverages that could be consumed safely during travel, and some others that are best avoided. Practical methods for water disinfection are: boiling for 1 min (or for 3 min at altitudes above 2, 000 m/6, 562 ft), or filtering through a 0.10 to 0.30 μm membrane in order to remove bacteria and protozoan parasites followed by chlorination or iodination to kill viruses. Travellers should remember to wash their hands with soap and running water or to use alcohol-based gels or solutions for a thorough hand-rub after going to the bathroom and before eating. In the case of infants, the best prevention measure is breastfeeding. Alternatively, infant formula should be prepared by using boiling hot water. Traveller's diarrhoea is also related to leisure activities such as swimming and diving in lakes or rivers, which are contaminated with human sewage or animal faeces. Consequently, travellers should choose to swim or dive in swimming-pools, which are kept properly sanitised and are regularly checked, even though protozoal cysts and viruses are resistant to usual levels of chlorination.

Duration: 1-3 days   Duration: >3 days

Passage of ≤ 5 stools / day   Passage of > 6 stools /   Passage of > 6 stools / day
  ± fever   day   • fever
No blood in stools   • blood in stools
                                                                          • tenasmus
Nausea, vomiting   Dehydration

Viral gastroenteritis   Bacterial   Enterotoxigenic   • Enteroinvasive bacteria
                             diarrhoea   bacteria (ETEC)   (Shigella, EAEC)
                                                                          • *E. histolytica*

Mild / moderate traveller's diarrhoea   **Severe traveller's diarrhoea**

Self-resolving / anti-diarrhoeal medication   Antibiotics
 ± antibiotics (specific travelling groups)

Diarrhoea occurring during travel (self-treatment, visit to the general practitioner) — Diagnosis based on clinical symptoms

---

Laboratory testing   MALARIA EXCLUDED

Routine haematology   **Stool culture   **Stool**   **Blood culture**
& biochemistry tests**   **PCR:** *Shigella*   **ova & parasite exam**
• Full blood count,   *Salmonella* | *Salmonella* |
  CRP   *Campylobacter*
                             LT and ST toxins of   Treatment
Inflammation   ETEC
indicators   aggR gene of EAEC
                            ipaH /invE genes of EIEC
• Blood urea nitrogen,   *B. fragilis* toxin genes of
  creatinine,   ETBF
  electrolytes   **RT- PCR:** noroviruses

Dehydration, renal
failure indicators

Positive result   Negative result

                                         False negative
                                         protozoa (?)

Treatment   Empirical
                                         metronidazole

                              No response   Recovery

                    Post-infectious irritable
                    bowel syndrome (?)
                    Upper + lower
                    gastrointestinal endoscopy

Diarrhoea occurring shortly after returning from travel or Diarrhoea persisting for more than a week after returning from travel (persistent traveller's diarrhoea) — Diagnosis based on clinical symptoms + paraclinical tests

Fig. 1. Diagnostic approach and management of traveller's diarrhoea.

Foods and beverages that can be consumed	Foods and beverages that would be better avoided
Dry items such as bread, biscuits, or dry foods Syrups, jellies, jams, honey Any foods carefully prepared in one's own apartment or hotel Cooked foods consumed hot Beverages served steaming hot Decontaminated water (through filtration, chlorination or iodination) Bottled water with intact seal apparent on opening Bottled carbonated drinks including soft drinks and beer Fruits peeled by the traveller	Moist foods served at room temperature including vegetables and meats Underdone meat and fish Hot sauces on tabletop Seafood Ice-creams Salads Milk and dairy products Prepared foods eaten cold Any food served buffet-style maintained at room temperature Hamburgers not served hot or at fast food service restaurants with rapid turnover of prepared hamburgers (hamburger toppings are a major concern in these areas) Tap water even in hotels claiming filtration systems Large quantities of ice Non-bottled drinks Fruits and vegetables with intact skins: berries, tomatoes Pre-peeled fruit

Table 3. Examples of foods and beverages that can be consumed and the ones better avoided.

8.2 Chemoprophylaxis
8.2.1 Non-antimicrobial agents
Bismuth subsalicylate has been shown to provide a 65 percent protection rate in cases of traveller's diarrhoea, when the typical dosage of 525 mg is orally given four times daily. Bismuth subsalicylate cannot be used for a period more than three weeks. Bismuth subsalicylate should be avoided in travelling children and in travellers on anticoagulants owing to the activity of the salicylate ions (Diemert, 2006; Ericsson, 2005)

8.2.2 Probiotics
Probiotics, such as *Lactobacillus rhamnosum* strain GG, *L. acidophilus*, *L. bulgaricus*, and *Saccharomyces boulardii*, are live microorganisms capable of colonizing the intestine, and thus competing with enteric pathogenic microorganisms. These strains may secrete antimicrobial agents, induce the production of mucin or modulate immune response. Use of probiotics can be considered an alternative prophylaxis against traveller's diarrhoea, even though the protection provided by them is still quite low with a rate of only 47 percent (Hilton et al., 1997; McFarland, 2007). No side effects were observed; yet in elderly or immunocompromised travellers and in travellers with an underlying condition, probiotcs should be prescribed with caution (DuPont, 2008).

8.2.3 Antibiotics

Pre-travel medical consultation should make the decision regarding the need and modality of antibiotic prophylaxis. The doctor and traveller should first discuss the plan and duration of the journey. Antibiotic prophylactic is only recommended for a select group of travellers (DuPont & Ericsson, 1993). Such a group comprises those with immunodeficiency, including travellers with AIDS or neoplasia, travellers undergoing treatment with immunosuppressants, travellers with an underlying condition, i.e. diabetes, that could be worsened by the diarrhoeal illness, and those with achlorhydria or hypochlorhydria due to gastrectomy, administration of a H_2 receptor blocker or a proton pump inhibitor.

Antibiotic prophylaxis may also be recommended for certain important business travels of short duration. Situations where such a use can be justified are: travel for negotiating and signing important business deals, politicians gathering for summits, athletes participating in international meetings, speakers making presentations at international conferences, or students travelling for a short duration to appear in an examination or any other similar situation. Antibiotic prophylaxis can induce a false sense of security in a traveller who may consequently relax the adherence to hygiene and other precautions. This raises the possibility of infection by resistant organisms and worse outcomes. Hypersensitivity to the prescribed antibiotic can be a serious problem during travel. Vaginal candidiasis is not uncommon in such cases and pseudomembranous colitis due to *Clostridium difficile* can be a serious illness (DuPont et al., 2009). Antibiotic prophylaxis should be taken with caution and the administration should never exceed a period of two to three weeks. Although small, the risk of emerging resistant strains should also be taken into account, since the antibiotics used for traveller's diarrhoea prophylaxis and treatment are the same. Fluoroquinolones provide up to 90 percent protection. The oral administration of ciprofloxacin, 500 mg once a day, or norfloxacin, 400 mg once a day, starts upon arrival at travel destination and continues for 24 to 48 hours after departure from areas of elevated risk of traveller's diarrhoea. With fluoroquinolones taken as a short-term prophylaxis, the risk of side effects is small. Yet the emergence of resistance not just for Enterobacteriaceae strains such as *Campylobacter* spp. as found in Southeast Asia, but also for strains of *Salmonella* spp. and *Shigella* spp. is a major concern. Such an occurrence could reverse the progress made so far in the prevention and management of traveller's diarrhoea (Kuschner et al., 1998; Lindgren et al., 2009; Mensa et al., 2008). This has not been a concern when using rifaximin in a dose of 200 mg orally twice a day. Rifaximin given orally is poorly absorbed (Koo et al., 2010). It offers a 58 to 77 percent protection rate and does not affect intestinal flora even after continuous administration for a period of two weeks (DuPont et al., 2005). Also, it can be used to prevent traveller's diarrhoea in children who are at least 12 years old.

8.3 Immunoprophylaxis and vaccines

Although diarrhoea due to heat-labile toxin (LT) producing ETEC is more frequent in travellers, the development of vaccines that protect against more than one pathogenic strain is challenging. Today, oral, inactivated vaccine against cholera, which consists of killed whole cell, or WC, *Vibrio cholerae* and the non-toxic, recombinant cholera toxin B-subunit, or BS, is the only vaccine proven to fight a form of traveller's diarrhoea. But it is only administered to specific travelling groups such as people involved in humanitarian aid and military personnel deployed overseas, if travelling to an area where they are going to be at unavoidable risk of exposure to cholera. Nevertheless, the amino acid sequences of cholera

toxin B subunit and LT toxin of ETEC share approximately 80 percent homology, thus implying that the WS/BS vaccine may also offer some protection against traveller's diarrhoea caused by enterotoxigenic *E. coli* (Hill et al., 2006). Unfortunately, since the temporary protection provided is moderate at a rate of only seven percent, the use of WC/BS vaccine against cholera is therefore not routinely recommended for the majority of travellers (Hill et al., 2006). Transcutaneous vaccine, comprising purified LT toxin of ETEC, does not appear to offer either statistically significant protection against ETEC or any in general protection against traveller's diarrhoea (Frech et al., 2008).

9. Treatment

Traveller's diarrhoea treatment includes rehydration, diet, antisecretory agents, antimotility drugs, and antibiotics.

9.1 Rehydration

Traveller's diarrhoea does not usually cause dehydration. If patients are otherwise healthy and are not dehydrated, they can drink water *ad libitum*. They can rehydrate by taking frequent, small sips of bottled/boiled water or a rehydration drink. Until diarrhoea subsides, patients should avoid consuming beverages with high osmolality or caffeine content. These drinks can aggravate diarrhoea (Ericsson et al., 2008). Fluid replacement with oral rehydration solution is necessary for the very young and the elderly travellers, since they are vulnerable to the effects of dehydration (Rose et al., 2010). Further, in potentially dehydrating diarrhoea cases, oral rehydration solution should be used by all age groups: excessive fluid loss is not a rare event among adult travellers to the developing countries, especially in South Asia, where enterotoxigenic *E. coli* is the predominant cause of traveller's diarrhoea (Table 1). In an attempt to maintain a good state of hydration, vigorous treatment of traveller's diarrhoea should start as soon as the diarrhoea begins (Ericsson et al., 2008; Rose et al., 2010).

9.2 Diet

Complete abstention from food is neither required nor recommended, since foods providing calories are necessary to facilitate renewal of mucosal cells lining the intestine (Lever & Soffer, 2009). Dietary restriction, on the whole, has been questioned lately except for food or drinks with high content of simple carbohydrates. Patients with traveller's diarrhoea have been advised to restrict lactose containing foods after correcting dehydration because of transient lactase deficiency (Ericsson et al., 2008). But no hard evidence has yet surfaced to support that dietary restriction benefits those travelling to developing countries (Gottlieb & Heather, 2011; Huang et al., 2004). Instead, frequent small meals, incorporating well cooked complex carbohydrates/starch such as mashed potatoes, rice or other cereals, are being generally encouraged. This may not be important for a well nourished adult traveller from a developed country but would be an important consideration in travellers, whose nutritional status is borderline and may be further affected by the loss of appetite (Ericsson et al., 2008).

9.3 Non-antimicrobial agents

Non-antimicrobial agents can be used in cases of travellers with mild to moderate diarrhoea. Bismuth subsalicylate is composed of a bismuth oxide core structure with salicylate ions

attached to the surface. It exerts antisecretory, antimicrobial and adsorbent effects to control diarrhoea, even though its exact mechanism still remains unknown. It was shown that bismuth subsalicylate can alleviate non-specific symptoms such as nausea in patients with traveller's diarrhoea (Hill & Beeching, 2011). The dosage of 525 mg is orally given every half hour eight times daily. In travellers with acquired immunodeficiency syndrome or with chronic enteric disease, bismuth absorption may occur across the damaged mucosa (DuPont et al., 2009b). Serious neurotoxic and nephrotoxic adverse events may be attributable to the use of bismuth (Bao, 2006). The highest concentrations of absorbed bismuth are found in the kidneys and liver (Fowler & Sexton, 2007). Bismuth subsalicylate should not be used by travellers with renal or hepatic impairment. Antisecretory racecadotril, 100 mg after the first loose stool followed by 100 mg three times daily up to seven days, which acts as a peripherally acting enkephlalinase inhibitor, is prescribed in patients with traveller's diarrhoea. In pediatric patients, it is given as an adjunct to oral rehydration therapy. Antimotility agents may be good for relieving the symptoms of traveller's diarrhoea and used as adjuncts to antibiotic treatment. Loperamide, the most widely used antimotility drug, is an opioid-receptors agonist, which does not affect the central nervous system, acts on the opioid receptors of the myenteric plexus of the large intestine and decreases intestinal movements. Two capsules are recommended as the initial dose and subsequently one capsule is given after each unformed stool, with clinical improvement being seen within 48 hours. Although it may trap pathogens in the intestine, loperamide may help travellers who cannot afford to have diarrhoea during a short-term trip of critical importance. It should not be given in the presence of mucus or blood in the stool with or without fever, which represents diarrhoea due to enteroinvasive bacteria. Loperamide may cause narcotic intoxication and ileus in young children and be responsible for severe constipation in the elderly (Galleli et al., 2010; Li et al., 2007). The use of antimotility agents by the pediatric and geriatric population is not always without risk and should perhaps be avoided.

9.4 Antibiotics

Antibiotics are used in moderate and severe traveller's diarrhoea. Such antimicrobial agents are fluoroquinolones, azithromycin and rifaximin (Table 4).

Fluoroquinolones, which are synthetic broad spectrum antibiotics, are active against invasive bacteria including *Shigella*, even though, mainly in Southeast Asia, resistance of *Campylobacter* to fluoroquinolones has emerged. In the latter case, azithromycin, which is a subclass of macrolide antibiotics, is recommended; it has high intracellular concentrations and serum-based definition of resistance does not necessarily apply to controlling the disease in a clinical situation. If the traveller wishes for a prompt relief from afebrile, gastrointestinal symptoms, loperamide can be taken in combination with one of the antibiotics mentioned above. Among travellers visiting Mexico, loperamide combined with azithromycin was shown to reduce the time from the last unformed stool when compared to those who were administered only azithromycin (Ericsson et al., 2007). Rifaximin, a novel semi-synthetic derivative of rifamycin, is active against ETEC but not against invasive bacteria (Taylor et al., 2008).

9.5 Self evaluation and treatment

Traveller's diarrhoea usually develops shortly after arrival at the travel destination. Study indicates that 80 percent of patients with traveller's diarrhoea choose to treat themselves

Antibiotic per os[a]	Adults' dosage (normal renal function)	Children's dosage (normal renal function)[b]
Fluoroquinolones		
Norfloxacin	800 mg once or 400 mg b.i.d. for 1-5 days	-
Levofloxacin	500 mg once or 500 mg q.d. for 1-5 days	-
Ofloxacin	400 mg once or 200 mg b.i.d. for 1-5 days	-
Ciprofloxacin	750 mg once or 500 mg b.i.d for 1-5 days	10-15 mg kg^{-1} b.i.d. for 3 days
Macrolide		
Azithromycin	500-1000 mg [c] once or 500mg q.d. for 3 days	20 mg kg^{-1} q.d. for 3 days
Rifamycin derivate		
Rifaximin	200 mg t.i.d.[d]	-

[a] Antibiotics taking should be interrupted in case of improvement
[b] Children's dose should not exceed adult dose
[c] 1000 mg azithromycin dose can cause nausea
[d] Rifaximin should not be administered in bloody diarrhoea

Table 4. Antibiotics dosage for moderate or severe traveller's diarrhoea.

irrespective of the illness being mild or more severe (Hill, 2000). For that reason, during pre-travel consultation, travellers should be given information about the problem and importance of traveller's diarrhoea and instructed on how to proceed with self-evaluation. Local medical help should be sought if diarrhoea lasts for more than 48 hours or in case of fever, blood or mucus in the stool. Otherwise, travellers could replace lost fluids and electrolytes and take non-antimicrobial agents in their possession. In high risk areas with difficult access to medical services, travellers should promptly start taking antibiotics (immediately after the symptoms appear, and before they get worse). The choice of antibiotic should be determined by the locally prevalent predominant organisms and their sensitivity pattern. Fluoroquinolones are usually recommended for most travel destinations excepting South and Southeast Asia, where azithromycin can be a better choice because of prevalence of fluoroquinolones-resistant *Campylobacter* (Table 1). For self-treatment, a single dose of antibiotics can be given. If there is no improvement, administration can continue for three days (Tribble et al., 2007). An otherwise healthy adult can take the antibiotics in combination with loperamide to achieve a faster improvement of diarrhoea (Ericsson et al., 2007).

10. Clinical course

All patients suffering from traveller's diarrhoea develop similar symptoms, regardless of the causal agent. It usually occurs within the first week of travel and resolves upon returning to the country of origin. The onset of traveller's diarrhoea is usually sudden, although abdominal pain, anorexia, and malaise may sometimes occur before the diarrhoea begins. Other manifestations such as nausea and vomiting in 10 to 25 percent, mild fever in up to 30

percent, and blood in stool in one to 10 percent of the cases may accompany diarrhoea. Average duration is approximately four days. Fifty percent of patients begin to recover within 48 hours (Steffen et al., 1983).

Irrespective of the aetiology, mild traveller's diarrhoea is generally short-term: this is not the case with more severe attacks (Hill, 2000). It is estimated that up to 25 percent of the cases of traveller's diarrhoea have more than five bowel movements in a day, and 30 to 45 percent of the cases may have their trip interrupted or travel plan altered for at least 12 to 24 hours (Steffen et al., 1987). Some patients with traveller's diarrhoea need to seek medical help while travelling or upon returning to the country of origin.

10.1 Viral gastroenteritis

Viral gastroenteritis is an intestinal infection caused by a variety of viruses resulting in mild, short-term diarrhoea, with vomiting being a prominent feature. It is often clinically undistiguishable from bacterial acute diarrhoea. In popular travel destinations, however, viruses have been shown to be responsible for up to 10 percent of cases of traveller's diarrhoea (Apelt et al., 2010). Viruses, mostly incriminated in cases of gastroenteritis, include GI and GII norovirus strains (Ajami et al., 2010) and rotaviruses belonging to groups A and C (Peñaranda et al., 1989; Sheridan et al, 1981). Enteric adenoviruses type 40 and 41 as well as astroviruses, though being an important cause of acute infantile gastroenteritis, do not appear to be a major health problem in travellers. Viruses can be transmitted from person to person or through contaminated food and water. Outbreaks of norovirus gastroenteritis have occurred in case of travellers co-existing in relatively confined spaces, such as aboard cruise ships and in tourist resorts, thus being in close contact with other passengers and tourists, relatively (Widdowson et al., 2002; Kornylo et al., 2009) Noroviruses cause transient malabsorption of D-xylose and fat, while rotaviruses cause malabsorption of glucose through the mechanism of cAMP protein kinase (Karst et al., 2010; Lorrot & Vasseur, 2007). Antibiotics do not work on viral gastroenteritis. Notwithstanding this, non-antimicrobial agents have been found effective in the treatment of intestinal viral infection associated with traveller's diarrhoea. Studies have shown that mixed viral and bacterial infections are common in gastroenteritis (Marshall, 2002). Thus, combination therapy with loperamide plus antibiotic is given empirically for traveller's diarrhoea (Ostrosky-Zeichner & Ericsson, 2001).

10.2 Persistent traveller's diarrhoea

Traveller's diarrhoea generally resolves even without treatment. However, in 10 percent of cases, digestive disturbances tend to persist for more than two weeks after the onset of the diarrhoea. In persistent cases, the patient continues to complain of intermittent or continuous gastrointestinal symptoms, such as loose stools, abdominal pain, bloating or other non-specific symptoms. Continued intestinal infection, post-infectious mucosal damage, or chronic gastrointestinal functional disorder may be responsible for persistent traveller's diarrhoea. In most of these cases, tests for the presence of pathogens may fail if sampling is delayed for a period of time after the onset (Connor, 2011).

10.2.1 Functional disorders

Similar to any acute inflammatory process, traveller's diarrhoea may disrupt the brush border microvilli of intestinal epithelial cells where disaccharidases reside. Consequently, a

transient lactose intolerance may occur. Likewise, transient malabsorption of xylose, folate and vitamin B12 may also occur (Lindenbaum, 1965). Another post-infectious sequela is the development of irritable bowel syndrome, or IBS. Among sufferers, five to 10 percent are likely to experience non-specific gastrointestinal symptoms that are compatible with those of irritable bowel syndrome. Also, it has been found that 10 percent of patients with irritable bowel syndrome have reported travelling abroad before the onset of their symptoms (DuPont et al., 2010). Travellers experiencing diarrhoea during their trip were five times more likely than travellers without to develop post-infectious irritable bowel syndrome, or PI-IBS (Stermer et al., 2006). In 15 percent of travellers, traveller's diarrhoea with serious symptoms can lead to post-infectious irritable bowel syndrome within a six month period (Okhyusen et al., 2004). Risk factors for developing post-infectious irritable bowel syndrome include female gender, young age, pre-existing anxiety or depression, fever or weight loss, and infection due to strains of *Campylobacter* with toxigenic properties (de la Cabada Bauche & DuPont, 2011). Following traveller's diarrhoea, transient changes in intestinal motility should may lead to stasis and small intestinal bacterial overgrowth. This can cause secondary diarrhoea, and other non-specific symptoms that resemble those of irritable bowel syndrome (Attar et al., 1999; Tureja et al., 2008).

10.2.2 Persistent intestinal infection

In acute traveller's diarrhoea, parasites account for only a small percentage of the cases. In persistent traveller's diarrhoea, by contrast, intestinal protozoa are the most frequently encountered aetiological agents. Where travellers develop persistent diarrhoea, the most commonly detected enteric protozoa are *Giardia, Cryptosporidium*, and *Entamoeba histolytica*, followed by a small percentage of cases caused by *Isospora belli* and microsporidia. In returning traveller patients, *Cyclospora cayetanensis* has also been suggested to cause diarrhoea that continues after travel. Risk factors that are associated with contracting intestinal protozoal infections while travelling abroad are quite well known: longer duration of stay, and the low level of hygiene and socio-economic development in the country travelled (Kansouzidou et al., 2004; Müller et al., 2001; Okhyunsen et al., 2001; Taylor et al., 1988).

11. Intestinal protozoal diarrhoeal disease

11.1 Giardiasis

Giardiasis is a disease of the small intestine caused by *Giardia*; it has recently been included in the World Health Organization 'Neglected Disease Initiative'. Clinical spectrum of *Giardia* infection may vary from asymptomatic carriage to acute and chronic diarrhoea with abdominal pain. *G. intestinalis* is a cosmopolitan flagellated protozoan of humans and other animals. Molecular analysis has demonstrated that *Giardia* isolates can be separated into at least eight genotypes or assemblages, namely A to H, that may show host preference (Lasek-Nesselquist et al., 2010). Humans are mostly infected by assemblages A and B. Genomic difference may underlie the often distinct difference in biology and clinical manifestations observed between the two assemblages. This implies that *Giardia* assemblage A and assemblage B may represent two distinct species (Franzén et al., 2009). *Giardia* infection is usually transmitted by ingesting cysts found in contaminated water or food, but human-to-human transmission has also been reported in situations of poor faecal–oral hygiene. Giardial encystation (when trophozoites pass through the small intestine to the colon) is

successful only if *Giardia* cysts are able to excyst after ingestion and entry into the small intestine (Lauwaet et al., 2007).

11.2 Amoebiasis

Amoebic colitis is characterized by gradual onset and symptoms present over a period of one to two weeks. It can thus be distinguished from bacterial dysentery. The protozoan may be responsible for various symptoms such as bloody diarrhoea and non-specific symptoms i.e. weight loss, fatigue, and abdominal pain. Also, it may cause fulminating dysentery. *Entamoeba*, whose habitat is the large intestine, is one of the most commonly detected enteric protozoans worldwide. It has been demonstrated that it comprises two species, *E. histolytica* and *E. dispar* and these cannot be morphologically differentiated from each other under the light microscope (Clark, 2004). However, these two species can be differentiated by using zymodeme patterns, monoclonal antibodies, or DNA probes (Stanley, 2003). Most recently, *E. histolytica* genome sequence has been re-annotated and re-assembled and data have been compared to closely related organisms (Lorenzi et al., 2010). Infection with *E. histolytica* is considered more prevalent in developing countries. It is transmitted by contaminated water and/or food or by the faecal-oral route. Immunocompromised persons as well as persons with a mental illness housed in institutional settings are at high risk for acquisition of amoebiasis. *Entamoeba* has two stages in its life cycle: active and motile trophozoite and the dormant cystic form. Trophozoite or the trophic form can be detected in the fresh unformed stool from a host. By contrast, cysts can survive outside the host, in the environment i.e. in water, in soils, or in food. *E. histolytica* is considered to be pathogenic, as opposed to the non-pathogenic *E. dispar*. Since *E. dispar* is regarded as non-pathogenic and commensal, infections with *E. dispar* are characteristically asymptomatic. Recently, however, there have been reports of patients infected with *E. dispar* experiencing gastrointestinal symptoms (Fotedar et al., 2007).

11.3 Cryptosporidiosis

In cryptosporidiosis caused by *Cryptosporidium*, immunocompetent individuals experience acute watery diarrhoea, which is usually self-limited and accompanied by non-specific symptoms such as abdominal pain, nausea and fatigue. In immunocompromised hosts, however, clinical manifestations of cryptosporidiosis vary with the level of immunosuppression. For instance, in case of low levels of CD4 helper T cells, immunocompromised patients could have persistent diarrhoea due to cryptosporidiosis (Brink et al., 2002). *Cryptosporidium* is an apicomplexan protozoan affecting humans and many animals. Molecular divergence between the two *C. parvum* variants, which were shown to have differences in epidemiological and clinical features, was discovered by using numerous techniques. These variants are now known as *C. parvum* in humans and in animals, and *C. hominis* in humans (Morgan-Ryan et al., 2002). A further important advance in the understanding of this protozoan is the publication of the *C. parvum* and *C. hominis* genome sequences. However, it has been suggested that there exist differences in the genetic make-up of *Cryptosporidium* populations, indicating variation in their infectivity for humans (Jex et al., 2008). In addition to genotypic differences, phenotypic differences have also been demonstrated suggesting that additional genetic pleomorphisms within the known genotypes exist. Monoxenous life cycle has an asexual stage, or sporozoites, and a sexual stage, or oocysts, and is completed within the small intestine. Sporulated thin-walled

oocysts are autoinfective. Thick-walled oocysts that transmit the cryptosporidial infection from one host to another are resistant forms, even in chlorinated water, upon being excreted (Currrent and Garcia, 1991). Cryptosporidial oocysts can be excreted for weeks after the diarrhoea subsides. *Cryptosporidium* can survive in source waters for a long period of time. Cryptosporidial infection is transmitted by drinking contaminated water or eating contaminated food, and by animal-to-human or faecal-oral routes. The infective dose is low. In healthy, immunocompetent people, ingestion of as few as up to 30 *Cryptosporidium* oocysts can cause infection, whereas in immunocompromised patients even fewer oocysts are required (DuPont et al., 1995).

11.4 Isosporiasis

Isosporiasis, a diarrhoeal illness that is caused by *Isospora belli*, generally causes watery diarrhoea and non-specific gastrointestinal symptoms such as cramps and abdominal pain. In immunocompetent individuals, isosporiasis is usually transient; however, immunocompromised patients can experience persistent diarrhoea resembling the cryptosporidial diarrhoea mentioned above (Mudholar & Namey, 2010). *I. belli* is a coccidian protozoan. Although ubiquitous, *I. belli* is more frequently encountered in the tropical and subtropical countries. Humans are the sole identified reservoir for *I. belli* infection. Transmission has not yet been elucidated, even though *I. belli* has been suggested to be transmitted through contaminated water. Similar to *Cryptosporidium*, the *I. belli* life cycle has an asexual stage and a sexual stage in the intestine. Oocysts are immature and incapable of infecting the human host after excretion. The large oocysts mature outside the body and become sporulated and infective within a two to three day period.

11.5 Cyclosporiasis

Cyclosporiasis, a diarrhoeal disease caused by *Cyclospora*, is generally the cause of self-limited diarrhoea accompanied by cramping, abdominal pain, nausea and other non-specific symptoms (Türk et al., 2004). Immunocompromised hosts, however, may experience prolonged diarrhoea that may become quite serious if left untreated (Türk et al., 2004). *C. cayetanensis* is a coccidian protozoan that has been associated with diarrhoea in the developing world. It is considered an obligatory intracellular parasite found in jejunum. *Cyclospora* reservoirs are yet to be defined, even though humans appear to be the only reservoir for *Cyclospora*, similar to *I. belli* (Ortega & Sanchez, 2010). It has been proposed that this coccidian protozoan parasite may be transmitted via contaminated water and food. In order to become infective, very large *Cyclospora* oocysts, which resemble those of *Cryptosporidium* but are roughly twice the size, need sporulation outside the body, in the environment: in this they are dissimilar to *Cryptosporidium* but similar to *I. belli*.

11.6 Microsporidiosis

Microsporidiosis is commonly found in immunosuppressed individuals (Matthis et al., 2005). Among the numerous microsporidian species, only *Enterocytozoon bieneusi* and *Encephalitozoon intestinalis* are associated with intestinal infection in humans worldwide. Therefore, infection with *E. bieneusi* or *E. intestinalis* should be considered in cases of chronic diarrhoea. Microsporidia are small, obligatory, intracellular organisms that infect vertebrate and invertebrate hosts. Although it has been proposed that they belong to the protist group of archezoa, microsporidia have molecularly been re-classified from protozoa to fungi or a

sister group of fungi (Parfrey et al., 2006). Microsporidia have specialized polar tubes, asexually reproduce within the cell, and form thick-walled spores that are capable of surviving in the environment for a long period of time.

11.7 Dientamoebiasis

Recently, *Dientamoeba fragilis* has been regarded as a pathogenic organism (Katz & Taylor, 2001). Most patients with dientamoebiasis report frequent unformed stools and abdominal pain. Mucus in the stool is sporadically observed. In about 30 percent of patients with dientamoebiasis, diarrhoea is persistent and may turn into the chronic form, which lasts more than four weeks, with abdominal pain being the predominant symptom (Stark et al., 2005). *D. fragilis* is one of the smaller parasites that can live in the human large intestine. Unlike other intestinal protozoa that are mainly detected in the developing world, *D. fragilis* is often seen in developed countries with high levels of hygiene. Once classified as an amoeba, it has been demonstrated to be a close relative of the trichomonads (Johnson et al., 2004). It is considered to be a non-flagellated trichomonad. It is worthwhile mentioning that *D. fragilis* has no apparent cyst-like forms (in this it is dissimilar to other intestinal protozoa). Although it still remains unclear (Barratt et al., 2011), it has been proposed that infection between humans occurs during the trophozoite stage. Our as-yet-unpublished results corroborate the possibility of intrafamily transmission (Stark et al., 2009).

11.8 Blastocystosis

Once thought to be a harmless inhabitant of the human gut, *Blastocystis* is now considered a potential pathogen. Immunocompromised or debilitated individuals seem more prone to getting a diarrhoea attributable to blastocystosis (Vassalos et al., 2008). *Blastocystis* sp. is a ubiquitous anaerobic protozoan parasite that lives in the intestine of humans, other animals and arthropods. *Blastocystis* isolates have been separated into at least 10 subtypes according to phylogenetic trees that have been constructed from sequences of the small subunit ribosomal RNA (Stensvold et al., 2009). Subtype 3 has been found to be the most common genotype (Tan, 2008). The protozoan is more frequently encountered in tropical and subtropical countries. *Blastocystis* is polymorphic. It has various morphological forms, including vacuolar, granular, amoeboid, cyst, multivacuolar and avacuolar forms, with the vacuolar form being the most commonly detected in stool examination. Amoeboid forms are predominantly seen in isolates from symptomatic patients (Tan, 2008). *Blastocystis* vacuolar forms could transit to *Blastocystis* cysts and vice versa. Thus, faecal–oral transmission has been proposed. Also, it is transmitted by contaminated water or by human-to human and animal-to-human routes.

11.9 Mechanisms of diarrhoea production

Diarrhoea caused by *Giardia* is mediated by increased rates of transit of small intestine origin as well as enhanced chloride secretion (Cotton et al., 2011). Yet the mechanisms of pathogenesis are poorly understood (Buret, 2007). However, host and parasite factors seem to contribute to the pathogenesis of *Giardia* infection. Increase in rates of enterocyte apoptosis and disruption of epithelial tight junctions lead to dysfunction in the small intestinal barrier resulting in activation of CD8 cytotoxic T-lymphocytes. CD8 lymphocytes may induce brush border microvilli injury and enterocyte malfunction that leads to malabsorption and maldigestion of small intestine origin (Buret, 2005). *Cryptosporidium* is

localized within a unique intracellular but extracytoplasmic niche (Tzipori & Ward, 2002). The coccidian parasite is found attached to brush border microvilli of epithelial cells of the small intestine where it can cause damage that leads to the death of enterocytes. To replace the damaged cells, cell division is triggered in the crypt region resulting for instance in hyperplasia. The absorptive function of the villar tips is impaired and chloride secretion by the crypt cells increases, thus leading to an overall enhancement of intestinal secretion. Under this proposed mechanism, *Cryptosporidium*-induced diarrhoea is classified as osmotic (Sears & Guerrant, 1994). The host immune system is likely to reduce the number of thin-walled oocysts in an attempt to prevent autoinfection, which tends to perpetuate cryptosporidial infection in the host. In principle, the mechanism of diarrhoea production appears to follow the same pattern as seen in isosporiasis and cyclosporiasis.

E. histolytica has been suggested to produce several potential virulence factors such as adhesins that enable adherence to the host cell, amoebapores that are capable of forming a hole in a target cell; and cysteine proteinases that can degrade extracellular matrix components. Intestinal inflamation, killing of mucosal cells and invasion of protozoan are the combined effects of these virulence factors (Padilla-Vaca & Anaya-Velázquez, 2010). Lysis of host neutrophils may also contribute to the cell damage. In a host-parasite interplay, however, it is quite possible that the virulence may reflect how much control the host is capable of exercising over invasion and replication of *Entamoeba* trophozoites (Galván-Moroyoqui et al., 2008). Invasion of intestinal epithelium by *Entamoeba* trophozoites can result in the development of dysentery, ulcers, or an amoeboma (Suriptiastuti, 2010). Dysenteric syndrome is characterized by the production of small volumes of bloody, mucoid stools without faecal leukocytes. Amoebic 'flask-shaped' ulcers can be observed in sections of the gastrointestinal tract. Amoeboma is the formation of amoebic granuloma in the intestinal wall. If entroinvasive illness turns into chronic amoebic colitis, the disease mimics inflammatory bowel disease. *D. fragilis* is considered to cause non-invasive, superficial irritation of the colonic mucosa, along with an eosinophilic inflammatory response (Johnson et al., 2004). *Blastocystis* is also considered to be the cause of non-invasive mucosal inflammation. Our published results have shown that *Blastocystis* subtype 3 might be pathogenic, only when amoeboid forms of *Blastocystis* are present (Katsarou-Katsari et al, 2008), and suggest that there are intra-specific differences within *Blastocystis* subtypes that contribute to the protozoan parasite's pathogenicity (Vassalos et al., 2010). The host immune status seems to play some role on the development of blastocystosis. Immunocompromised patients will suffer from diarrhoeal disease as the potential pathogenic forms of *Blastocystis* thrive when host defences are weakened. Interplay with intestinal microbiota may differ between pathogenic and non-pathogenic forms of *Blastocystis* (Vassalos et al., 2008). *E. bieneusi* clusters have been found in intestinal and biliary tract cells, whereas *E. intestinalis* infects the intestinal tract and may also disseminate to the mesenteric nodes and kidney. In the context of host-parasite relationship, microsporidia seem to be highly sophisticated parasites. Not only is proteome complexity reduced in the microsporidia but also several eukaryotic pathways are pared down to what appears to be minimal functional units so that host cell manipulation can be achieved (Williams, 2009).

11.10 Routine diagnostic arsenal

The challenge is to identify the likely intestinal protozoal agent involved in diarrhoeal disease as fast and accurately as possible so that therapeutic management can start.

Conventional ova and parasite testing that involves light microscopic examination of stool samples is employed for the low cost detection of intestinal protozoal diarrhoeal disease. The method, however, is a labour intensive and time consuming process, and requires an experienced microscopist. On the other hand, antigen detection assays are considered to be rapid and reliable methods for detecting enteric protozoan parasites, without the need for skilled microscopy. Direct fluorescent antibody, enzyme-linked immunosorbent assay (ELISA), and rapid dipstick-like tests are the diagnostic procedures in use for antigen detection in diagnosis of protozoa of the intestine.

Giardial infection can be diagnosed by identification of cysts and trophozoites in the stool; wet mount preparations and trichrome stained smears of stool specimens are the recommended procedures. *Entamoeba* cysts and trophozoites can also be observed by examining a fresh stool and by using trichrome stain. *Cryptosporidium* oocysts can be visualized with a modified acid fast stain. Similarly, identification of *Isospora* oocysts requires acid fast staining. To detect *Cyclospora*, however, Safranin stain is used. *Cyclospora* can also be identified in stool samples, since the protozoan is able to autofluoresce at 330 to 380 nm under ultraviolet microscopy. Microsporidial infection can be diagnosed by identification of free and intracytoplasmic spores with Giemsa and modified trichrome, or with fluorochrome stains such as calcofluor and Uvitex 2B, stains that have an affinity for chitin. Morphological differences between *E. bieneusi* and *E. intestinalis* can be made out in small intestine biopsy specimens by electron microscopy.

It is possible to detect *Giardia* by using direct immunofluorescence or ELISA. *Cryptosporidium* oocysts can be detected by using monoclonal antibody-based direct immunofluorescence assay or ELISA. Newly developed stool antigen detection methods, i.e. ELISA, capable of discriminating between *E. histolytica* and *E. dispar* may also prove particularly useful. For laboratory diagnosis of the enteric protozoans *G. intestinalis*, *E. histolytica*, and *Cryptosporidium* spp., diagnostic kits using immunochromatography are now commercially available. To detect microsporidia, free and intracytoplasmic spores can be examined using an indirect immunofluorescent assay with monoclonal antibodies.

PCR-based methods are also increasingly used for the detection of intestinal protozoa in case of diarrhoea. Inexpensive in-house PCR protocols can be adapted to detect intestinal protozoa. Furthermore, the trend has been moving from the detection of a single intestinal protozoal agent involved in diarrhoeal disease to a multiplex approach, thus allowing simultaneous identification of multiple protozoan parasites in order not to loose valuable time (Stark et al., 2011). In our laboratory, nested multiplex PCR is routinely used to differentiate *E. histolytica* from the non-pathogenic *E. dispar* (Evangelopoulos et al., 2000). As for the differentiation of intestinal protozoa other than *Entamoeba* spp. at the inter- or intra-specific level, further refinements are required in PCR-based methods. Thus, outbreaks of intestinal protozoal diarrhoeal disease could be readily investigated and research in molecular epidemiology could be made possible. Polymerase chain reaction techniques, such as real time PCR based on SYBR-Green fluorescence, can also be used to simultaneousley identify microsporidial species (Polley et al. 2011). In diarrhoeal patients with dientamoebiasis, highly variable intermittent shedding of *D. fragilis* trophozoites has been shown to confound diagnosis when methods such as microscopy, culture or conventional PCR are used to detect the protozoan. However, intermittent shedding does not seem to interfere with the diagnosis of dientamoebiasis in cases where real time PCR, which demonstrates high sensitivity, is employed. This is thus being seen as the method of choice (Stark et al., 2010).

11.11 Treatment and management

The agents that are used for the treatment of intestinal protozoal diarrhoeal diseases are set out in Table 5. Concerning the treatment of giardiasis, there are several drugs including the 5-nitroimidazole and benzimidazole derivatives, quinacrine, furazolidone, paromomycin, and nitazoxanide that have been proved effective and approved. Metronidazole is considered the antiprotozoal agent of choice for the treatment of giardial infection; however, decreased susceptibility to metronidazole has been reported. Therefore, albendazole can alternatively be administered. Combination therapy may also be used when first line drugs fail, nitazoxanide is not available, or co-infection with other parasites occurs (Lopez-Velez et al., 2010).

Where cysts are detected in an asymptomatic *Entamoeba* carrier, a luminal agent, such as diloxanide or paromomycin, should be given to treat intraluminal infection and clear amoebic cysts (Stanley, 2003). In enteroinvasive disease, i.e. severe colitis due to *E. histolytica,* tissue penetrating metronidazole should be administered against invasive trophozoites and then a luminal amoebicide should be given to kill any remaining cysts. Using *in vivo* models, metronidazole was found to be the most effective (Becker et al., 2011). However, if metronidazole tolerance occurs, tinidazole may alternatively be used (Gonzales et al., 2009). Cryptosporidial infection is self-limited and immunocompetent hosts may only need to be treated supportively. In immunocompromised patients with cryptosporidiosis, the most commonly used agents are paromomycin, and azithromycin, which are partially effective. Nitazoxanide, a thiazoline compound, has been shown to be effective in immunocompetent individuals. However, nitazoxanide could be effective in case immune response is appropriate (Gargala, 2008). Consequently, in immunocompromised patients, it is necessary to combine treatment against cryptosporidial infection with a therapy for restoring immunity (Cabada & White, 2010).

In cases of symptomatic *Isospora* or *Cyclospora* infections, trimethoprim-sulfamethoxazole, a sulfonamid antibiotic, is administered. In immunocompromised patients experiencing recurrent diarrhoeal disease, secondary prophylaxis with trimethoprim-sulfamethoxazole attempts to treat *Isospora* or *Cyclospora* infection, and thus prevent relapses. Nitazoxanide is also in use for the treatment of isosporiasis and cyclosporiasis in patients with sulfa allergy (Zimmer et al., 2007).

Microsporidial infection of immunocompetent individuals is self-limited and does not require antiparasite treatment. Many agents have been tested in the treatment of microsporidia infection. However, the results have shown variable therapeutic success in the treatment of microsporidiosis in humans. Albendazole has been demonstrated to be effective against *Encephalitozoon* spp. such as *E. intestinalis* but not against *Enterocytozoon bieneusi*. Fumagillin, an irreversible inhibitor of methionine aminopeptidase-2, has been demonstrated to be effective for eradicating *E. bieneusi,* despite its side effects. In renal transplant recipients, fumagillin shows acceptable safety when monitoring immunosuppressive therapy (Champion et al., 2010).

Currently, there is no consensus for the treatment of symptomatic dientamoebiasis (Johnson et al., 2004). The therapeutic agents commonly used to treat *D. fragilis* infection are metronidazole, paromomycin, newer nitroimidazole derivatives such as secnidazole and ornidazole, tetracycline, or a combination therapy.

Concerning *Blastocystis* infections, the treating agents that are currently in use have been considered to be generally effective. However, decreased susceptibility to metronidazole has

Protozoa	Drug(s) of choice	Alternative drug(s)
Giardia intestinalis	Metronidazole 250 mg t.i.d. × 5 days Tinidazole 2 g × 1 day	Albendazole 400 mg q.d. × 5 days Quinacrine 100 mg t.i.d. × 5 days Paromomycin 25 – 30 mg kg^{-1} per day in 3 doses × 7 days
Entamoeba histolytica	*Asymptomatic carriers (cysts)* Paromomycin 500 mg t.i.d. × 10 days Diloxanide furoate 500 mg t.i.d. × 10 days *Symptomatic patients (trophozoites)* Metronidazole 750 mg t.i.d. × 5 days or Tinidazole 2 g × 3 days followed by paromomycin 500 mg t.i.d. × 10 days or diloxanide furoate 500 mg t.i.d. × 10 days	Diloxanide furoate 500 mg t.i.d. × 10 days plus Tetracycline 250 mg q.i.d. × 10 days followed Chloroquine 500 mg q.i.d. × 7 days
Cryptosporidium.	Nitazoxanide 500 mg b.i.d. × 3- 14 days	Albendazole 400 mg b.i.d.x 7-14 days Paromomycin 500 mg t.i.d. × 14 days
Isospora belli	Trimethoprim- Sulfamethoxazole (160mg/800mg) b.i.d. × 10days	Ciprofloxacin 500mg b.i.d. × 7 days Pyrimethamine 75 mg q.d. plus folinic acid 10 mg q.d. × 10 days
Cyclospora cayatensis	Trimethoprim- Sulfamethoxazole (160mg/800mg) q.i.d. ×10days	Nitazoxanide 500 mg b.i.d. × 3- 14 days
Encephalitozoon intestinalis	Albendazole 400 mg b.i.d. × 14-28 days	
Enterocytozoon bieneusi	Albendazole 400 mg b.i.d. × 28 days	Fumagillin 60 mg q.d. × 14 days
Dientamoeba fragilis	Tetracycline 500 mf q.i.d. × 10 days	Paromomycin 25 – 30 mg kg^{-1} per day in 3 doses × 7 days Metronidazole 750 mg t.i.d. × 5- 10 days
Blastocystis sp.	Nitazoxanide 500 mg b.i.d. × 3 days	Metronidazole 750 mg t.i.d. × 5- 10 days Trimethoprim- Sulfamethoxazole (160mg/800mg) b.i.d. × 7 days

Table 5. Treatment of diarrhoeal disease due to intestinal protozoa: drugs of choice and alternative drugs.

been described. An asymptomatic *Blastocystis* carrier should be followed up so that a thorough examination could be ordered in case symptoms become evident. The use of broad spectrum antimicrobial should be restrained, being used only in cases of symptomatic *Blastocystis* infections. Thus, the emergence of resistant *Blastocystis* strains should be prevented (Vassalos et al., 2008).

12. Conclusion

Since the mid-1950s when the term 'emporiatrics' was coined by Waters and Kean, substantial progress has been made in dealing with traveller's diarrhoea. Rather than being seen as an unavoidable scourge for the hapless tourist, traveller's diarrhoea has been considered an illness that requires further investigation and fuller action. Currently, an increasing number of pathogens likely to be responsible for traveller's diarrhoea have been identified (Jiang et al., 2010). Concerning classical enteropathogens, such as ETEC, the mode of action and regulation by host factors is known. Also, progress in prophylaxis has been dramatic. Old, but still good, advice for sound eating and drinking habits can now be coupled with drug administration.

When taking only chemoprophylaxis, travellers may be at a lower risk of contracting traveller's diarrhoea but they are not 100 percent immune from a variety of pathogens likely to be responsible for the illness. Travellers would be thus in error if they assume that they are safe and pay no attention to hygiene and sanitation rules (Wagner & Wiedermann, 2009). There has been sustained research effort for a vaccine that would be effective against ETEC, the leading cause of traveller's diarrhoea, and reduce the duration and severity of the symptoms. A vaccine, which combines cholera toxin subunit B with killed whole cell (W/rBS), is currently being assessed in clinical trials (Svennerholm, 2010).

Concerning traveller's diarrhoea treatment, the emergence of resistance against antibiotics has led to research for novel drugs or therapeutic regimens. In the United States, rifaximin has now been approved for the treatment of traveller's diarrhoea attributable to non-invasive *E. coli*. Rifaximin is still being evaluated for the prevention of traveller's diarrhoea (Armstrong et al., 2010).

In any such cases, prompt management is currently recommended, since it has been proved that induced intestinal irritation may lead to temporary or prolonged functional disorders, as is the case with persistent traveller's diarrhoea that is mainly of parasitic origin (Connor, 2011). Intestinal protozoa found in travellers complaining of persistent diarrhoea upon their return home from exotic destinations have practically been the sole enteric protozoa detected in the industrialized countries. Owing to high levels of hygiene and food safety, there has been a dramatic decline in infections caused by intestinal protozoa in the developed countries. In the last decades, however, intestinal infections due to opportunistic protozoa have emerged because of a marked increase in the number of immunocompromised individuals from a range of causes. Also, immigration from and adventurous travel to developing tropical countries with low hygienic level and a high prevalence of ubiquitous enteric protozoa have recently increased. Therefore, lately, cases of intestinal protozoal diarrhoeal disease have been increasing in the developed world.

This re-emergence has rekindled interest in research on intestinal protozoa. Inter- or intra-specific genotype differences may help explain variations in phenotypic features, various pathogenic mechanisms, and the presence of virulence factors of enteric protozoa. For *E. histolytica*, the parasite lifestyle was examined at the whole-genome level so that new genes

encoding virulence factors along with signaling pathways and processes could be identified (Lorenzi et al. 2010; Weedal & Neil Hall, 2011). Ongoing research on host and parasite factors likely to contribute to the pathogenesis of giardiasis may elucidate assemblage-specific pathogenic mechanisms (Cotton et al., 2011). New potential drug targets have been discovered in an attempt to develop the next generation of antiprotozoals. Researchers test novel promising drugs that target unique proteins and metabolic pathways of the protozoan *G. intestinalis* (Lale et al. 2010). Others continue to attempt to develop an antiprotozoal agent that would be effective against the coccidian *Cryptosporidium*. Nitazoxanide, which was discovered in the 1980s, has routinely been considered an alternative treatment option in case of diarrhoeal disease due to *Giardia*, *Entamoeba*, *Isospora* and *Cyclospora*. In immunocompromised hosts, however, nitazoxanide fails to treat cryptosporidiosis unless it is combined with antiretroviral therapy, perhaps because of partial antiparasitic effect of protease inhibitors (Cabada & White, 2010). Despite its side effects, fumagillin is used for treating microsporidia infections. Fumagillin analogs have recently been shown to be active against *E. histolytica* (Arico-Muendel et al., 2009). Concerning dientamoebiasis and blastocystosis, the ambiguity that surrounds the mode of transmission of *D. fragilis* (Barratt et al., 2011) and the pathogenic stage of *Blastocystis* (Vassalos et al., 2008; Tan, 2008) complicates the management of these intestinal infections. Likewise, the role of interplay between host defence mechanisms and intestinal protozoan survival strategies is complex. Further investigation of host-parasite relationship is of critical importance in the design and implementation of new vaccines and candidate drugs.

13. Acknowledgement

14. References

Adachi, J.A.; Mathewson, J.J.; Jiang, Z.D.; Ericsson, C.D. & DuPont, H.L. (2002). Enteric pathogens in Mexican sauces of popular restaurants in Guadalajara, Mexico, and Houston, Texas. *Annals of Internal Medicine* Vol.136, No.12, (June 2002), pp. 884–88, ISSN 0003-4819

Ajami, N.; Koo, H.; Darkoh, C.; Atmar, R.L.; Okhuyesen, P.C.; Jiang, Z.-D.; Flores, J. & DuPont, H.L. (2010). Characterization of norovirus-associated traveler's diarrhea. *Clinical Infectious Diseases*, Vol.51, No.2, (July 2010), pp. 123-130, ISSN 1058-4838

Alon, D.; Shitrit, P.& Chowers, M. (2010). Risk behaviors and spectrum of diseases among elderly travelers: a comparison of younger and older adults. *Journal of Travel Medicine*, Vol.17, No.4, (July-August 2010), pp. 250-255, ISSN 1195-1982

Anderson, E.J. & Weber, S.G. (2004). Rotavirus infection in adults. *The Lancet Infectious Diseases*, Vol.4, No.2, (February 2004), pp. 91-99, ISSN 1473-3099

Apelt, N.; Hartberger, C.; Campe, H. & Löscher, T. (2010). The prevalence of norovirus in returning international travelers with diarrhea. *BMC Infecioust Diseases*, Vol.10, No.131, (May 2010), pp. 1-6, ISSN 1471-2334 (Electronic)

Arico-Muendel, C.; Centrella, P.A.; Contonio, B.D.; Morgan, B.A.; O'Donovan, G.; Paradise, C.L.; Skinner, S.R.; Sluboski, B.; Svendsen, J.L.; White, K.F.; Debnath, A.; Gut, J.; Wilson, N.; McKerrow, J.H.; DeRisi, J.L.; Rosenthal, P.J. & Chiang, P.K. (2009). Antiparasitic activities of novel, orally available fumagillin analogs. *Bioorganic and Medicinal Chemistry Letters*, Vol.19, No.17, (September 2009), pp. 5128-5131. ISSN 0960-894X

Armstrong, A.W.; Ulukan, S.; Weiner, M.; Mostafa, M.; Shaheen, H.; Nakhla, I.; Tribble, D.R. & Riddle, M.S. (2010). A randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of rifaximin for the prevention of travelers' diarrhea in US military personnel deployed to Incirlik Air Base, Incirlik, Turkey. *Journal of Travel Medicine*, Vol.17, No.6, (November-December 2010), pp. 392-394. ISSN 1195-1982

Attar, A.; Flourié, B.; Rambaud, J.C.; Franchisseur, C.; Ruszniewski, P. & Bouhnik, Y. (1999). Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: A crossover, randomized trial. *Gastroenterology*, Vol.117, No.4, (October 1999), pp. 794 – 820, ISSN 0016-5085

Bandres, J.C.; Mathewson, J.J. & DuPont, H.L. (1998). Heat susceptibility of bacterial enteropathogens. Implicationsfor the prevention of travelers' diarrhea. *Archives of Internal Medicine*, Vol.148, No.19, (October 1988), pp. 2261–2263, ISSN 003-0026

Bao, R. (2006). Bismuth. In, *Goldfrank's Toxicologic Emergencies*. N. Flomenbaum, L.W. Goldfrank, R. Hoffman, M.A. Howland, N. Lewin & L. Nelson (Ed.), McGraw-Hill Companies, Inc. , 1269- 1273, ISBN 0-07-147914-7, New York, USA

Barratt, J.L.; Harkness, J.; Marriott, D.; Ellis, J.T. & Stark, D. (2011). The ambiguous life of *Dientamoeba fragilis*: the need to investigate current hypotheses on transmission. *Parasitology*, Vol.138, No.5, (April 2011), pp.557-572. ISSN 0031-1820

Becker, S.; Hoffman, P. & Houpt, E.R. (2011). Efficacy of antiamebic drugs in a mouse model. *The American Journal of Tropical Medicine and Hygiene*, Vol.84, No.4, (April 2011), pp. 581-586, ISSN 0002-9637

Borg, M. (2007). Food hygiene and gastroenteritis. In, *IFIC Basic Concepts of Infection Control*, C. Friedman & W. Newsom (Eds.), International Federation of Infection Control, 163-170, ISBN 978-0-9555861-0-1, Portadown, UK

Brink, A.K.; Mahe, C.; Watera C.; Lugada E.; Gilks, C.; Whitworth, J. & French, N. (2002). Diarrhea, CD4 counts and enteric infections in a community-based cohort of HIV-infected adults in Uganda. *The Journal of Infection,* Vol.45, No.2, (August 2002), pp. 99-106. ISSN: 0163-4453

Buret, A.G. (2005). Immunopathology of giardiasis: the role of lymphocytes in intestinal epithelial injury and malfunction. *Memórias do Instituto Oswaldo Cruz*, Vol.100, Suppl.1, (March 2005), pp. 185-190. ISSN 0074-0276

Buret, A.G. (2007). Mechanisms of epithelial dysfunction in giardiasis. *Gut*, Vol.56, No.3, (March 2007), pp. 316-317. ISSN 0017-5749

Cabada, M.M. & White, A.C. Jr. (2010). Treatment of cryptosporidiosis: do we know what we think we know? *Current Opinion in Infectious Diseases*, Vol.23, No.5, (October 2010), pp.494-499, ISSN 0951-7375

Cailhol, J. & Bouchaud, O. (2007). [Turista: traveler's diarrhea]. *Presse Medicale* , Vol.36, No.4-C2, (April 2007), pp. 717-722, ISSN 0075-4982

Chapin, A.R.; Carpenter, C.M.; Dudley, W.C.; Gibson, L.C.; Pratdesaba, R.; Torres, O.; Sanchez, D.; Belkind-Gerson, J.; Nyquist, I.; Kärnell, A.; Gustafsson, B.; Halpern, J.L.; Bourgeois, A.L. & Schwab, K.J. (2005). Prevalence of norovirus among visitors from the United States to Mexico and Guatemala who experience traveler's diarrhea. *Journal of Clinical Microbiology*, Vol.43, No.3, (March 2005), pp. 1112-1117, ISSN 0095-1137

Champion, L.; Durrbach, A.; Lang P; Delahousse, M.; Chauvet, C.; Sarfati, C.; Glotz, D. & Molina, J.M. (2010). Fumagillin for treatment of intestianl microsporidiosis in reanl transplant recipients. *American Journal of Transplantation*, Vol.10, No.8, (August 2010), pp. 1925-1930, ISSN 1600-6135

Clark, C.G. (2004). *Entamoeba histolytica* and *Entamoeba dispar*, the non-identical twins, In, *The Pathogenic Enteric Protozoa:* Giardia, Entamoeba, Cryptosporidium *and* Cyclospora, C.R. Sterling & R.D. Adam (Eds), 15-26, Kluwer Academic Publishers, ISBN 1-4020-7794-7, Boston MA, USA

Clemens, J.D.; Sack, D.A.; Harris, J.R.; Chakraborty, J.; Neogy, P.K.; Stanton, B.; Huda, N.; Khan, M.U.; Kay, B.A. & Khan, M.R. (1988). Cross-protection by B subunitwhole cell cholera vaccine against diarrhea associated with heat-labile toxinproducing enterotoxigenic *Escherichia coli*: results of a large-scale field trial. *The Journal of Infectious Diseases*, Vol.158, No.2, (August 1988), pp. 372-377, ISSN 0022-1899

Connor, B.A. (2011). Persistent travelers' diarrhea, In: *CDC Health Information for International Travel 2012*, G. W. Brunette (Ed.), 537-549, Oxford University Press, ISBN 978-0-19-976901-8, New York, USA

Cotton, J.A.; Beatty, J.K. & Buret, A.G. (2011). Host parasite interactions and pathophysiology in *Giardia* infections. *International Journal of Parasitology*, (June 2011), doi:10.1016/j.ijpara.2011.05.002, ISSN 0029-7519

Current, W.L. & Garcia, L.S. (1991). Cryptosporidiosis. *Clinical Microbiology Reviews*, Vol.3, No.4, (June 1991), pp. 325-358, ISSN 0893-8512

Diemert, D.J. (2006). Prevention and self-treatment of traveler's diarrhea. *Clinical Microbiology Reviews*, Vol.19, No.3, (July 2006), pp. 583-594, ISSN 0893-8512

Domènech-Sánchez, A.; Juan, C.; Rullan, A.J.; Pérez, J.L. & Berrocal, C.I. (2009). Gastroenteritis outbreaks in 2 tourist resorts, Dominican Republic. *Emerging Infectious Diseases*, Vol.15, No.11, (November 2009), pp. 1877-1878, ISSN 1080-6040

DuPont, H.L. (2008) Systematic review: prevention of travellers'diarrhoea. *Alimentary Pharmacology and Therapeutics*, Vol.27, No.9, (May 2008), pp. 741–751, ISSN 0269-281

DuPont, H.L. & Ericsson, C.D .(1993). Prevention and treatment of traveler ' s diarrhea . *The New England Journal of Medicine*, Vol.328, No.25, (June24, 1993), pp. 1821 – 1827, ISSN 0028-4793

DuPont, H.L. & Khan, F.M. (1994). Travelers' diarrhea: Epidemiology, microbiology, prevention, and therapy. *Journal of Travel Medicine*, Vol.1, No.2, (June 1994) pp. 84-93, ISSN 1708-8305

DuPont, H.L.; Ericsson, C.D. & DuPont, M.W. (1986). Emporiatric enteritis: lessons learned from U.S. students in Mexico. *Transactions of the American Clinical and Climatological Association*. Vol. 97, pp. 32–42, ISSN 0065-7778

DuPont, H.L.; Chappell, C.L.; Sterling, C.R.; Okhuysen, P.C.; Rose, J.B. & Jakubowski, W. (1995). The infectivity of *Cryptosporidium parvum* in healthy volunteers. *The New England Journal of Medicine*, Vol.180, No.332, (March 1995), pp. 855-859, ISSN 0028-4793

DuPont, H.L.; Jiang, Z.D.; Okhuysen, P.C.; Ericsson, C.D.; de la Cabada, F.J.; Ke, S.; DuPont, M.W. & Martinez-Sandoval, F. (2005). A randomized, blind, placebo-controlled trial of rifaxin to prevent traveler's diarrea. *Annals of Internal Medicine*, Vol.142, No.3, (May 2005), pp. 805-812, ISSN 0003-4819

DuPont, H.L.; Ericsson, C.D.; Farthing, M.J.; Gorbach, S.; Pichering, L.K.; Rombo, L.; Steffen, R. & Weinke, T. (2009a). Expert review of the evidence base for prevention of travelers' diarrhea. *Journal of Travel Medicine*, Vol.16, No.3, (May-June 2009), pp. 149-160, ISSN 1195-1982

DuPont, H.L.; Ericsson, C.D.; Farthing, M.J.; Gorbach, S.; Pichering, L.K.; Rombo, L.; Steffen, R. & Weinke, T. (2009b). Expert review of the evidence base for self-therapy of travelers' diarrhea. *Journal of Travel Medicine*, Vol. 16, No. 3, (May-June 2009), pp. 161–171, ISSN 1195-1982

DuPont, H.L.; Galler, G.; Garcia-Torres, F.; Dupont, A.W.; Greisinger, A. & Jiang, Z.D. (2010). Travel and travelers' diarrhea in patients with irritable bowel syndrome. *The American Journal of Tropical Medicine and Hygiene*, Vol.82, No.2, (February 2010), pp. 301-305, ISSN 0002-9637

El-Ganayni, G.A.; Attia, R.A; & Motawea, S.M. (1994). The relation between ABO blood groups, HLA typing and giardiasis in children. *Journal of the Egyptian Society of Parasitolology*, Vol.24, No.2, (August 1994), pp. 407-412, ISSN 0253-5890

Ericsson, C.D. (2005).Nonantimicrobial agents in the prevention and treatment of traveler´s diarrhea. *Clinical Infectious Diseases*, Vol.41, Suppl.8, (December 2005), pp. S557-S563, ISSN 1058-4838

Ericsson, C.D.; DuPont, H.L.; Okhuysen, P.C.; Jiang, Z.D.& DuPont, M.W. (2007). Loperamide plus azithromycin more effectively treats travelers' diarrhea in Mexico than azithromycin alone. *Journal of Travel Medicine*, Vol.14, No.5, (September-October 2007), pp. 312–319, ISSN 1195-1982

Ericsson, C.D.; DuPont, H.L. & Steffen, R. (2008). *Travelers' Diarrhea*. BC Decker Inc, ISBN 998-1-55009-371-1, Hamilton , Ontario.

Evangelopoulos, A.; Spanakos, G.; Patsoula, E.; Vakalis, N. & Legakis, N. (2000). A nested, multiplex, PCR assay for the simultaneous detection and differentiation of *Entamoeba histolytica* and *Entamoeba dispar* in faeces. *Annals of Tropical Medicine and Parasitology*, Vol.94, No.3, (April 2000), pp. 233-240, ISSN 0003-4983

Flores, J.; DuPont, H.L.; Lee, S.A.; Belkind-Gerson, J.; Paredes, M.; Mohamed, J.A.; Armitige, L.Y.; Guo, D.C.; & Okhuysen, P.C. (2008) . Influence of host interleukin-10 polymorphisms on development of traveler's diarrhea due to heat-labile enterotoxin- producing Escherichia coli in travelers from the United States who are visiting Mexico. *Clinical and Vaccine Immunology*. Vol.15, No.8, (August 2008), pp. 1194–1198, ISSN 1556-6811

Fotedar, R.; Stark, D.; Beebe, N.; Marriott, D.; Ellis, J. & Harkness, J. (2007). Laboratory diagnostic techniques for *Entamoeba* species. *Clinical Microbiology Reviews*, Vol.20, No.3, (July 2007), pp. 511-532, ISSN 0893-8512

Fowler, B.A. & Sexton, M.J. (2007). Bismuth. In, *Handbook on the Toxicology of Metals,Third Edition*, G.F. Nordberg; B.A., Fowler; M. Nordberg & L., Friberg (Eds), 117, Academic Press/Elsevier B.V., ISBN 978-0-12-369413-3, Burlington MA, San Diego CA, London UK

Frachtman, R.L.; Ericsson, C.D. & DuPont, H.L. (1982). Seroconversion to *Entamoeba histolytica* among short-term travelers to Mexico. *Archives of Internal Medicine*, Vol.142, No.7, (July 1982), pp. 1299. ISSN 0003-9926

Franzén, O.; Jerlström-Hultqvist, J.; Castro, E.; Sherwood, E.; Ankarklev, J.; Reiner, D.S.; Palm, D.; Andersson, J.O.; Andersson, B. & Svärd, S.G. (2009). Draft genome sequencing of *Giardia intestinalis* assemblage B isolate GS: Is human giardiasis caused by two different species? *PLoS Pathogens*, Vol.5, No.8, (August 2009), e1000560. ISSN 1553-7366

Frech, S.A.; DuPont H.L.; Bourgeois, A.L.; McKenzie, R.; Belkind-Gerson, J.; Figueroa, J.F.; Okhuysen, P.C.; Guerrero, N.H.; Martinez-Sandoval, F.G.; Meléndez-Romero, J.H.; Jiang, Z.D.; Asturias, E.J.; Halpern, J.; Torres, O.R.; Hoffman, A.S.; Villar, C.P.; Kassern, R.N.; Flyer, D.C.; Andersen, B.H.; Kazempour, K.; Breich, S.A.& Glenn, G.M..(2008). Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. *The Lancet*, Vol. 71, No.9629, (June 14, 2008), pp. 2019–2025, ISSN 0140-6736

Freedmann, D.O.; Weld, L.H.; Kozarsky, P.E.; Fisk, T.; Robins, R.; von Sonnenburg F.; Keystone, J.S.; Pandey, P.; Cetron, M.S. & Geosentinel Surveillance Network (2006). Spectrum of disease and relation to place of exposure among ill returned travelers. *The New England Journal of Medicine*, Vol.354, No 2, (January 2006), pp. 119–130, ISSN 0028-4793

Gallelli, L.; Colosimo, M.; Tolotta G.A.; Falcone, D.; Luberto, L.; Curto, L.S.; Rende, P.; Mazzei, F.; Marigliano, N.M.; De Sarro, G. & Cucchiara, S. (2010). Prospective randomized double-blind trial of racecadotril compared with loperamide in elderly people with gastroenteritis living in nursing homes. *European Journal of Clinical Pharmacology*, Vol.66, No.2, (February 2010), pp. 137-44. ISSN 0031-6970

Galván-Moroyoqui, J.M.; Del Carmen Dominguez-Robles, M. & Meza, I. (2008). The interplay between *Entamoeba* and enteropathogenic bacteria modulates epithelial cell damage. *PloS Neglected Tropical Diseases*, Vol.2, No.7, (July 2008), e266. ISSN 1935-2727

Gargala, G. (2008). Drug treatment and novel drug target against *Cryptosporidium*. *Parasite*, Vol.15, No.3, (September 2008), pp. 275-281, ISSN 1252-607X

Gonzales, M.L.; Dans, L.F. & Martinez, E.G. (2009). Antiamoebic drugs for treating amoebic colitis. *Cochrane Database for Systematic Reviews*, Vol.15, No.2, (April 2009), CD006085. ISSN 1469-493X

Goodgame, R. (2003). Emerging Causes of Traveler's Diarrhea: Cryptosporidium, Cyclospora, Isospora, and Microsporidia. *Current Infectious Disease Reports*, Vol.5, No 5, (February 2003), pp. 66-73, ISSN 1523-3847

Gottlieb, T & Heather, C.S. (2011). Diarrhoea in adults (acute). *Clinical Evidence [Electronic Resource]*, Vol.pii, No.0901, (February 2011), ISSN 1752-8526

Harris, J.B.; Khan. A.J.; LaRosque, R.C.; Dorer, D.J.; Chowdhury, F.; Faruque, A.S.; Sack, D.A.; Ryan, E.T.; Qardi, F. & Caldewood, S.B.. (2005). Blood group, immunity, and risk of infection with Vibrio cholerae in an area of endemicity. *Infection and Immunity*, Vol.73, No.11, (November 2005), pp. 7422-7427, ISSN 1098-5522

Hill, D.R (2000). Occurrence and self-treatment of diarrhea in a large cohort of Americans traveling to developing countries. . *The American Journal of Tropical Medicine and Hygiene*, Vol.62, No.5, (May 2000), pp. 585-589, ISSN 0002-9637

Hill, D.R.; Ford, L. & Lalloo, D.G. (2006). Oral cholera vaccines: use in clinical practice.*The Lancet Infectious Diseases*, Vol.6, No 6, (June 2006), pp. 361–373, ISSN 1473-3099

Hill, D.R. & Beeching, N.J. (2010). Travelers' diarrhea. *Current Opinion in Infectious Diseases*, Vol.23, No.5, (October 2010), pp.481-487, ISSN 0951-7375

Hilton, E.; Kolakowski, P.; Singer, C. & Smith, M. (1997) Effi cacy of *Lactobacillus* GG as a diarrheal preventive in travelers. *Journal of Travel Medicine*, Vol.4, No.1, (March 1997), pp. 41–43, ISSN 1195-1982

Houf, K. & Stephan, R.(2007). Isolation and characterization of the emerging foodborn pathogen *Arcobacter* from human stool. *Journal of Microbiological Methods*, Vol. 68, No. 2, (February 2007), pp. 408-413, ISSN 0167-7012

Huang, P.; Farkas, T.; Marionneau, S.; Zhong, W. ; Ruvoën-Clouet, N. ; Morrow, A.L.; Altaye, M.; Pickering, L.K.; Newburg, D.S.; LePendu, J & Jiang, X..(2003). Noroviruses bind to human ABO, Lewis, and secretor histo-blood group antigens: identification of 4 distinct strainspecific patterns. *The Journal of Infectious Diseases,* Vol.188, No.1, (July 2003), pp. 19-31, ISSN 0022-1899

Huang, D.B.; Awasthi, M.; Le B.M.; Leve, M.E.; DuPont, M.W.; DuPont, H.L. & Ericsson, C.D. (2004). The role of diet in the treatment of travelers' diarrhea: A pilot study. *Clinical Infectious Diseases*, Vol.39, No.4, (August 2004), pp. 468-471, ISSN 1058-4838

Hutson ,A.M.; Atmar, R.L.; Graham, D.Y. & Estes, M.K. (2002). Norwalk virus infection and disease is associated with ABO histo-blood group type. *The Journal of Infectious Diseases*. Vol.185, No.9. (May 2002), pp. 1335-1337, ISSN 0022-1899

Jex, A.R.; Pangasa, A.; Campbell, B.E.; Whipp, M.; Hogg, G.; Sinclair, M.I.; Stevens, M. & Gasser, R.B. (2008). Classification of *Cryptosporidium* species from patients with sporadic cryptosporidiosis by use of sequence-based multilocus analysis following mutation scanning. *Journal of Clinical Microbiology*, Vol.46, No.7, (July 2008), pp. 2252-2262, ISSN 0095-1137

Jiang, Z.D.; Okhuysen, P.C.; Guo, D.C.; He, R.; King, T.M.; DuPont, H.L. & Milewicz, D.M. (2003). Genetic susceptibility to enteroaggregative Escherichia coli diarrhea: polymorphism in the interleukin-8 promotor region.*The Journal of Infectious Diseases*, Vol.188, No.4, (15 August 2003), pp. 506-511, ISSN 0022-1899

Jiang, Z.D.; DuPont, H.L.; Brown, E.L.; Nandy, R.K.; Ramamurthy, T.; Sinha, A.; Ghosh, S.; Guin, S.; Gurleen, K.; Rodrigues, S.; Chen, J.J.; McKenzie, R. & Steffen, R. (2010). Microbial etiology of travelers' diarrhea in Mexico, Guatemala, and India: importance of enterotoxigenic *Bacteroides fragilis* and *Arcobacter* species. *Journal of Clinical Microbiology,* Vol.48, No.4, (April 2010), pp. 1417-1419, ISSN 0095-1137

Johnson, E.H.; Windsor, J.J. & Clark, C.G. (2004). Emerging from Obscurity: Biological, Clinical, and Diagnostic Aspects of *Dientamoeba fragilis*. *Clinical Microbiology Reviews*, Vol.17, No.3, (July 2004), pp. 553-570, ISSN 0893-8512

Johnson, P.C.; Ericsson, C.D.; DuPont, H.L.; Morgan, D.R.; Bitsura, J.A & Wood, L.V. (1986). Comparison of loperamide with bismuth subsalicylate for the treatment of acute travelers' diarrhea. *JAMA: the Journal of the American Medical Association*, Vol.255, No.6, (14 February 1986), pp. 757–760, ISSN 1538-3598

Kansouzidou, A.; Charitidou, C.; Varnis, T.; Vavatsi, N, & Kamaria, F. (2004). Cyclospora cayetanensis in a patient with travelers' diarrhea: case report and review. J*ournal of Travel Medicine*, Vol.11, No.1, (January-February 2004), pp. 61-63, ISSN 1195-1982

Karst, S.M. (2010). Pathogenesis of noroviruses, emeging RNA viruses. *Viruses*, Vol.2, No.3, (2010), ISSN 1999-4915

Katsarou-Katsari, A.; Vassalos, C.M.; Tzanetou, K.; Spanakos, G.; Papadopoulou, C & Vakalis, N. (2008). Acute urticaria associated with amoeboid forms of *Blastocystis* sp. subtype 3. *Acta Dermato-venereologica*, Vol.88, No.1, (January 2008), pp. 80-81, ISSN 0001-5555

Katz, D.E. & Taylor, D.N. (2001). Parasitic infections of the gastrointestinal tract. *Gastroenterology Clinics of North America*, Vol.30, No.3, (September 2001), pp. 797-815, ISSN 0889-8553

Koo, D., Maloney, K. & Tauxe, R. (1996). Epidemioplogyof diarrheal disease outbreaks on cruise ships, 1986 through 1993. *JAMA: the Journal of the American Medical Association*, Vol. 275, No. 7, (Februar 1996), pp, 545-547, ISSN 1538-3598

Koo, H.L., Jiang, Z.D., Brown, E., Garcia, C., Qi ,H.& DuPont, H.L. (2008). Coliform contamination of vegetables obtained from popular restaurants in Guadalajara, Mexico, and Houston, Texas. *Clinical Infectious Diseases*, Vol.47, No.2, (July 2008), pp. 218–221, ISSN 1-58-4838

Koo, H.L. & DuPont, H.L. (2010). Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. *Current Opinion in Gastroenterology*, Vol.26, No.1, (January 2010), pp. 17–25, ISSN 0267-1379

Kornylo, K.; Kim, D.K.; Widdowson, M.A.; Turabelidze, G. & Averhoff, F.M. (2009). Risk of norovirus transmission during air travel. *Journal of Travel Medicine*, Vol.16, No.5, (September-October 2009), pp. 349-351, ISSN 1195-1982

Kuschner, R.A.; Trofa, A.F; Thomas, R.J.; Hoge, C.W.; Pitarangsi, C.; Amato, S.; Olafson, R.P.; Echeverria, P.; Sadoff, J.C. & Taylor, D.N. (1998). Use of azitromicyn for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. *Clinical Infectious Diseases*, Vol.21, No.3, (September 1998), pp.341-345, ISSN 1058-4838

Lalle, M. (2010). Giardiasis in the post genomic era: treatment, drug resistance and novel therapeutic perspectives. *Infectious Disorders Drug Targets*, Vol.10. No.4, (August 2010), pp. 283-294. ISSN 1871-5265

Lama, J.R.; Seas, C.R.; León-Barúa, R.; Gotuzzo, E. & Sack, R.B. (2004). Environmental temperature, cholera, and acute diarrhoea in adults in Lima, Peru. *Journal of Health, Population and Nutrition*, Vol.22, No.4, (December 2004), pp. 399-403, ISSN 1606-0997

Lasek-Nesselquist, E.; Welch, D.M. & Sogin, M.L. (2010). The identification of a new *Giardia duodenalis* assemblage in marine vertebrates and a preliminary analysis of *G.*

duodenalis population biology in marine systems. *International Journal of Parasitology*, Vol.40, No.9, (August 2010), pp. 1063-1074, ISSN 0029-7519

Lauerman, J.F. (2001). Weathering diarrheal illness effects of El Niño in the South Pacific. Environmental Health Perspectives, Vol.109, No.2, (February 2001), pp. A84–A85, ISSN 0091-6765

Lauwaet, T.; Davids, B.J.; Reiner, D.S. & Gillin, F.D. (2007). Encystation of *Giardia lamblia*: a model for other parasites. *Current Opinion in Microbiology*, Vol.10, No.6, (December 2007), pp.554-559, ISSN 1369-5274

Leder K.(2009). Intestinal Protozoa: *Giardia, Amebiasis, Cyclospora, Blastocystis hominis, Dientamoeba fragilis*, and *Cryptosporidium parvum.* In, *Tropical Diseases in Travele*rs, E. Schwartz (Ed), 294-302, Blackwell Publishing, ISBN 978-1-4051-8441-0, The Atrium, Southern Gate, Chichester, West Sussex, UK

Lever, D.S. & Soffer, E. (2009). Acute diarrhea. In, *Current Clinical Medicine 2009/ Cleveland Clinic*, W.D. Carey, (Ed). Saunders Elsevier Inc., 474-478, ISBN 978-1-4160-6643-9, Philadelphia, USA

Li, S.T.; Grossman, D.C. & Cummings, P. (2007). Loperamide therapy for acute diarrhea in children: systematic review and meta-analysis. *PLoS Medicine*, Vol. 4, No.3, (March 2007), e98. ISSN 1549-1277

Lindenbaum, J. (1965). Malabsorption during and after recovery from acute intestinal infection . *BMJ* , Vol.2, No.5457, (August 1965), pp. 326 – 329, ISSN 0007-1447

Lindgren, M.M.; Kotilainen, P.; Huovinen, P.; Hurme, S.; Lukinmaa, S.; Webber, M.A.; Piddock, L.J.; Siitonen, A.; & Hakanen, A.J. (2009) Reduced fl uoroquinolone susceptibilityin *Salmonella enterica* isolates from travelers, Finland. *Emerging Infectious Diseases*, Vol. 5, No.5, (May 2009), pp. 809–812, ISSN 1080-6059

Lopez-Velez, R.; Batle, C.; Jiménez, C.; Navarro, M.;Norman, F. & Perez-Molina, J. (2010). Short Course Combination Therapy for Giardiasis after Nitroimidazole Failure. *The American Journal of Tropical Medicine and Hygiene*, Vol.83, No.1, (July 2010), pp. 171-173, ISSN 0002-9637

Lorenzi, H.A.; Puiu, D.; Miller, J.R.; Brinkac, L.M.; Amedeo, P.; Hall, N. & Caler, E.V. (2010). New assembly, reannotation and analysis of the *Entamoeba histolytica* genome reveal new genomic features and protein content information. *PloS Neglected Tropical Diseases*, Vol.4, No.6, (June 2010), e716, ISSN 1935-2727

Lorrot, M. & Vasseur, M. (2007). How do the rotavirus NSP4 and bacterial enterotoxins lead differently to diarrhea? Virology Journal, Vol.4, (March 2007), pp.1-6, ISSN 1743-422X

Marionneau, S.; Airaud, F.; Bovin, N.V.; Pendu ,J.L. & Ruvoen-Clouet, N. (2005). Influence of the combined ABO, FUT2, and FUT3 polymorphism on susceptibility to Norwalk virus attachment. *The Journal of Infectious Diseases*, Vol.192, No.6, (September 2005), pp. 1071-1077, ISSN 0022-1899

Marshall, J.A. (2002). Mixed infections of intestinal viruses and bacteria in humans. In, *Polymicrobial diseases*, K.A. Brogden & J.A. Guthmiller (Eds.), ASM Press, 299-316, ISBN 1-55581-244-9, Washington, USA

Mathis, A.; Weber, R. & and Deplazes, P. (2005). Zoonotic potential of the microsporidia. *Clinical Microbiology Reviews*, Vol.18, No.3, (July 2005), pp. 423-445, ISSN 0893-8512

Mattila, L.; Siitonen, A.; Kyronseppa, H.; Simula, I.; Oksanen, P.; Stenvik, M,; Salo, P.& Peltola, H..(1992). Seasonal variation in etiology of traveler's diarrhea. Finnish-

Moroccan Study Group. *The Journal of Infectious Diseases*, Vol.165, No.2, (February 1992), pp. 385-388, ISSN 0022-1899

McFarland, L.V. (2007). Meta-analysis of probiotics for the prevention of traveler's diarrhea. *Travel Medicine and Infectious Disease*, Vol.5, No.2, (March 2007), pp. 97–105, ISSN 1873-0442

Mensa, L.; Marco, F.; Vila, J.; Gascon, J. & Ruiz, J. (2008) Quinolone resistance among *Shigella* spp. isolated from travellers returning from India. *Clinical Microbiology and Infection,* Vol.14, No.3, (March 2008), pp. 279–281 , ISSN 1469-0691

Meraz, I.M.; Jiang, Z.D.; Ericsson, C.D.; Bourgeois, A.L.; Steffen, R.; Taylor, D.N.;Hernandez, N. & DuPont, H.L. (2008).Enterotoxigenic *Escherichia coli* and diffusely adherent *E. coli* as likely causes of a proportion of pathogen-negative travelers' diarrhea—a PCR-based study. *Journal of Travel Medicine,* Vol.15, No.6, (November- December 2008), pp. 412-418, ISSN 1195-1982

Mohamed, J.A.; DuPont, H.L.; Jiang, Z.D.; Belkind-Gerson, J.; Figueroa, J.F.; Armitige, L.Y.; Tsai, A.; Nair, P.;Martinez-Sandoval, F.J.; Guo, D.C.; Hayes, P. & Okhuysen, P.C. (2007). A novel single-nucleotide polymorphism in the lactoferrin gene is associated with susceptibility to diarrhea in North American travelers to Mexico. *Clinical Infectious Diseases*, Vol.44, No.7, (April 2007), pp. 945–952, ISSN 1058-4838

Mohamed, J.A.; DuPont, H.L.; Jiang, Z.D.; Flores, J.; Carlin, L.G.;Belkind-Gerson, J.; Martinez-Sandoval, F.G.; Guo, D.; White, A.C. Jr & Okhuysen, P.C. (2009). A single-nucleotide polymorphism in the gene encoding osteoprotegerin, an anti-inflammatory protein produced in response to infection with diarrheagenic Escherichia coli, is associated with an increased risk of nonsecretory bacterial diarrhea in North American travelers to Mexico. *The Journal of Infectious Diseases*, Vol.199, No.4, (February 2009), pp. 477–485, ISSN 0022-1899

Morgan-Ryan, U.M.; Fall, A.; Ward, L.A.; Hihjjawi, N.; Sulaiman, I.; Fayer, R.; Thompson, R.C.; Olson, M.; Lal, A. & Xiao, L. (2002). *Cryptosporidium hominis* n. sp. (Apicomplexa: Cryptosporidiidae) from *Homo sapiens. The Journal of Eukaryotic Microbiology,* Vol.49, No.6, (November-December 2002), pp. 433-440, ISSN 1066-5234

Mudholkar, V.G. & Namey, R.D. (2010). Heavy infestation of *Isospora belli* causing severe watery diarrhea. *Indian Journal of Pathology & Microbiology*, Vol.53, No.4, (October-December 2010), pp. 824-825, ISSN 0377-4929

Müller, A.; Bialek, R.; Kämper, A.; Fätkenheuer, G.; Salzberger, B. & Franzén. C.(2001). Detection of micosporidia in travelers with diarrhea. *Journal of Clinical Microbiology,* Vol.39, No.4, (April 2001), pp. 1630-1632, ISSN 0095-1137

Navaneethan, U. & Giannella, R.A. (2008). Mechanisms of infectious diarrhea. *National Clinical Practice. Gastroenterology and Hepatology,* Vol.5, No.11, (November 2008), pp. 637-647, ISSN 1743-4378

Norman, F.F.; Pérez-Molina, J.; Pérez de Ayala, A.; Jiménez, B.C.; Navarro, M. & López-Vélez R. (2008). Clostridium difficile-associated diarrhea after antibiotic treatment for traveler's diarrhea. *Clinical Infectious Diseases*, Vol.46, No.7, (April 2008), pp. 1060-1063, ISSN 1058-4838

Okhuysen, P.C. (2001). Traveler's diarrhea due to intestinal protozoa. *Clinical Infectious Diseases*, Vol.33, No.1, (July 1, 2001), pp. 110–114, ISSN 1058-4838

Okhuysen, P.C. (2005). Current concepts in traveler´s diarrhea: epidemiology, antimicrobial resistance and treatment. *Current Opinion in Infectious Diseases*, Vol.18, No.6, (December 2005), pp.522-526, ISSN 0951-7375

Okyuysen, P.C.; Jiang, Z.D.; Carlin, L.; Forbes, C. & DuPont, H.L. (2004). Postdiarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. *The American Journal of Gastroenterology*, Vol.99, No.9, (September 2004), pp. 1774–1778, ISSN 0002-9270

Ortega, Y.R. & Sanchez, R. (2010). Update on *Cyclospora cayetanensis*, a food-borne and waterborne parasite. *Clinical Microbiology Reviews*, Vol.23, No.1, (January 2010), pp. 218-234, ISSN 0893-8512

Ostrosky-Zeichner, L. & Ericsson, C.D. (2001). Travelers' diarrhea. In: *Travel Medicine*, J.N. Zuckerman (Ed.), 153-164, John Wiley & Sons, Ltd, ISBN 0-471-49079-2, Chichester, UK

Padilla-Vaca, F. & Anaya-Velázquez , F. (2010). Insights into *Entamoeba histolytica* virulence modulation. *Infectious Disorders Drug Targets*, Vol.4, No.10, (August 2010), pp.242-250, ISSN 1871-5265

Paredes-Paredes, M.: Okhuysen, P.C.; Flores, J.; Mohamed, J.A.; Padda, R.S.; Gonzalez-Estrada, A.; Haley, C.A.; Carlin, L.G.; Nair, P. & DuPont, H.L. (2011). Seasonality of diarrheagenic *Escherichia coli* pathotypes in the US students acquiring diarrhea in Mexico. *Journal of Travel Medicine*, Vol.18, No.2, (March-April 2011), pp. 121-125, ISSN 1195-1982

Parfrey, L.W.; Barbero, E.; Lasser, E.; Dunthorn, M.; Bhattacharya, D.; Patterson, D.J. & Katz, L.A. (2006). Evaluating support for the current classification of eukaryotic diversity. *PloS Genetics*, Vol.2, No.12, (December 2006), e220. ISSN 1553-7390

Peñaranda, M.E.; Cubitt, W.D.;Sinarachatanant, P.; Taylor, D.N.; Likanonsakul, S.; Saif, L. & Glass, R.I. (1989). Group C rotavirus infections in patients with diarrhea in Thailand, Nepal, and England. *Journal of Infectious Diseases*, Vol.160, No.3, (September 1989), pp. 392-397, ISSN 0022-1899

Pitzinger, B.; Steffen, R. & Tschopp, A.(1991). Incidence and clinical features of traveler's diarrhea in infants and children. *The Pediatric Infectious Disease Journal*, Vol.10, No.10. (October 1991), pp. 719-723, ISSN 0891-3668

Piyaphanee, W.; Kusolsuk. T.; Kittitrakul, C.; Suttithym, W.; Ponam, T. & Wilairatana, P. (2011). Incidence and impact of travelers' diarrhea among foreign backpackers in Southeast Asia: a result from Khao San road, Bangkok. *Journal of Travel Medicine*. Vol.18, No.2, (March-April 2011), pp. 109-114, ISSN 1195-1982

Polley, S.D.; Boadi, S.; Watson, J.; Curry, A. & Chiodini P.L. (2011). Detection and species identification of microsporidial infections using SYBR Green real-time PCR. *Journal of Medical Microbiology*, Vol.60, Pt4, (April 2011), pp. 459-466, ISSN 0022-2615

Rose, S.R.; Keystone, J.S. & Hackett, P. (2010). Travelers' Diarrhea. In, *International Travel Health Guide. Updated Online Edition, 2010,* Chapter 6, Travel Medicine, Inc., Northampton MA, (March 14, 2010), Retrieved from http://www.travmed.com/health_guide.htm

Sanders, J.W.; Riddle, M.S.; Brewster, S.J. & Taylor, D.N. (2008). Epidemiology of traveler's diarrhea. In, *Travel Medicine*, J.S. Keystone; P.E. Kozarsky; D.O. Freedman; H.D. Nothdurft & B.A. Connor (Eds.), Chapter 16, Mosby Elsevier, 2008, ISBN 0323034535, Maryland Heights, USA

Sari Kovats, R.; Buma, M.J.; Hajat, S.; Worrall, E. & Haines, A. (2003). El Nino and health. *The Lancet*, Vol.362, No.9394, (November 2003), pp. 1481-1489, ISSN 0140-6736

Sears, C.L. & Guerrant, R.L. (1994). Cryptosporiodiosis: the complexity of intestinal pathophysiology. *Gastroenterology*, Vol.106, No.1, (January 1994), pp. 252–254, ISSN 0016-5085

Shah, N.; DuPont, H.L. & Ramsey, D.J. (2009). Global etiology of travelers' diarrhea: systematic review from 1973 to the present. *The American Journal of Tropical Medicine and Hygiene*, Vol.80, No.4, (April 2009), pp. 609-614, ISSN 0002-9637

Sheridan, J.F.; Aurelian. L.; Barbour, G.; Santosham, M.; Sack, R.B. & Ryder, R.W. (1981). Traveler's diarrhea associated with rotavirus infection: analysis of virus-specific immunoglobulin classes. *Infection and Immunity*, Vol.31, No.1, (January1981), pp. 419-429, ISSN 0019-9567

Stanley, S.L. Jr. (2003). Amoebiasis. *The Lancet*, Vol.361, No.9362 (March 2003), pp. 1025-1034, ISSN 0140-6736

Stark, D.; Al-Qassab, S.E.; Barratt, J.L.; Stanley, K.; Roberts, T.; Marriott, D.; Harkness, J. & Ellis, J.T. (2011). Evaluation of multiplex tandem real-time PCR for detection of *Cryptosporidium* spp., *Dientamoeba fragilis*, *Entamoeba histolytica*, and *Giardia intestinalis* in clinical stool samples. *Journal of Clinical Microbiology*, 2011 Jan;Vol.49, No.1, (January 2011), pp. 257-262, ISSN 0095-1137

Stark, D.; Barratt, J.; Ellis, J.; Harkness, J & Marriott, D. (2009). Repeated *Dientamoeba fragilis* infections: a case report of two families from Sydney, Australia. *Infectious Diseases Reports*, Vol.1, e4, (November 2009). ISSN 20367430

Stark, D.; Barratt, J.; Roberts, T.; Marriott, D.; Harkness, J. & Ellis, J. (2010). Comparison of microscopy, two xenic culture techniques, conventional and real-time PCR for the detection of *Dientamoeba fragilis* in clinical stool samples. *European Journal of Clinical Microbiology and Infectious Disease*, Vol.29, No.4, (April 2010), pp. 411-416. ISSN 0934-9723

Stark, D.; Beebe, N.; Marriott, D.; Ellis, J. & Harkness, J. (2005). Prospective study of the prevalence, genotyping, and clinical relevance of *Dientamoeba fragilis* infections in an Australian population. *Journal of Clinical Microbiology*, Vol.43, No.6, (June 2005), pp. 2718-2723, ISSN 0095-1137

Steffen, R.; van der Linde, F.; Gyr. K. & Schär, M. (1983). Epidemiology of diarrhea in travelers. *JAMA: the Journal of the American Medical Association*, Vol.249, No.9, (March 1983), pp. 1176-1180, ISSN 1538-3598

Steffen, R.; Rickenbach, M.; Wilhelm, U.; Helminger, A. & Schär, M. (1987). Health problems after travel to developing countries. *The Journal of Infectious Diseases*, Vol.156, No.1, (July 1987), pp. 84-91, ISSN 0022-1899

Steffen, R.; Collard, F.; Tornieporth, N.; Campbell-Forrester, S.; Ashley, D., Thompson, S.; Mathewson, J.J.; Maes, E.; Stephenson, B.; DuPont, H.L. & von Sonnenburg, F. (1999). Epidemiology, etiology, and impact of traveler's diarrhea in Jamaica. *JAMA: the Journal of the American Medical Association*, Vol.281, No.9, (March 1999), pp. 811-817, ISSN 1538-3598

Steffen, R. (2005). Epidemiology of traveler's diarrhea. *Clinical Infectious Diseases*. Vol. 41, Suppl. 8,(December 2005), pp. S536–S540, ISSN 1058-4838.

Stensvold, C.R.; Alfellani, M.A.; Nørskov-Lauritsen, S.; Prip, K.; Victory, E.L.; Maddox, C.; Nielsen, H.V. & Clark, C.G. (2009). Subtype distribution of Blastocystis isolates

from synanthropic and zoo animals and identification of a new subtype. *International Journal of Parasitology*, Vol.39, No.4, (March 2009), pp.473-479, ISSN 0029-7519

Stermer, E; Lubezky, A.; Potasman, I.; Paster, E. & Lavy, A. (2006).Is traveler's diarrhea a significant risk factor for the development of irritable bowel syndrome? A prospective study. *Clinical Infectious Diseases*, Vol.43, No.7, (October 2006), pp. 898-901, ISSN 1058-4838

Suriptiastuti, M.S. (2010). Host-parasite interactions and mechanisms of infections in amebiasis. *Universa Medicina*, Vol.29, No.2, (May-August 2010), pp. 104-113, ISSN 1907-3062

Svennerholm, A.M. (2011). From cholera to enterotoxigenic *Escherichia coli* (ETEC) vaccine development. *The Indian Journal of Medical Research*, Vol.133, No,2, (February 2011), pp. 188-196. ISSN:0971-5916

Synder, J.D. & Blake, P.A. (1982). Is cholera a problem a problem for US travelers? *JAMA: the Journal of the American Medical Association*, Vol.247, No.16, (23 April), pp. 2268-2269, ISSN 1538-3598

Tan, K.S. (2008). New insights on classification, identification, and clinical relevance of *Blastocystis* spp. *Clinical Microbiology Reviews*, Vol.21, No.4, (October 2008), pp. 639-665, ISSN 0893-8512

Taylor, D.N. & Echeverria, P. (1986). Etiology and epidemiology of traveler's diarrhea in Asia. *Review of Infectious Diseases*, Suppl.2, (May-June 1986), pp. S136-141, ISSN 0162-0886

Taylor, D.N.; Houston, R.; Shlim, D.R.; Bhaibulaya, M.; Ungar, B.L. & Echeverria, P. (1988). Etiology of diarrhea among travelers and foreign residents in Nepal. *JAMA: the Journal of the American Medical Association*, Vol.260, No.9, (September 1988), pp. 1245–1248, ISSN 1538-3598

Taylor, D.N.; McKenzie, R.; Durbin, A.; Carpenter, C.; Haake, R. & Bourgeois, A.L. (2008). Systemic pharmacokinetics of rifaximin in volunteers with shigellosis. *Antimicrobial Agents and Chemotherapy*, Vol.52, No.3, (March 2008), pp. 1179–1181, ISSN 0066-4804

Teague, N.S.; Srijan, A.; Wongstitwilairoong, B.; Poramathikul, K.; Champathai, T.; Ruksasiri, S.; Pavlin, J. & Mason, C.J. (2010). Enteric pathogen sampling of tourist restaurants in Bangkok, Thailand. *Journal of Travel Medicine*, Vol.17, No.2, (March-April 2010), pp. 118-123, ISSN 1195-1982

Tjoa, W.S.; DuPont, H.L.; Sullivan, P.; Pickering, L.K.; Holguin, A.H.; Olarte, J.; Evans, D.G.; Evans, D.J. Jr. (1977). Location of food consumption and travelers' diarrhea. *Amercan Journal of Epidemiology*, Vol.106, No.1, (July 1977), pp. 61-66, ISSN 0002-9262

Topazian, M. & Bia, F.J. (1994). New parasites on the block: emerging intestinal protozoa. *Gastroenterologist*, Vol.2, No.2, (June 1994), pp. 147-159, ISSN 1065-2477

Tribble, D.R.; Sanders. J.W.; Pang, L.W.; Mason.; C; Pitarangsi, C.; Baqar, S.; Armstrong, A.; Hshieh, P.; Fox, A.; Maley, E.A.; Lebron, C.; Faix, D.J., Lawler, J.V.; Nayak., G., Lewis, M., Bodhidatta, L. & Scott, D.A. (2007). Traveler's diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycinbased regimens with a 3-day levofloxacin regimen. *Clinical Infectious Diseases*, Vol.44, No.3, (February 2007), pp. 338–346, ISSN 1058-4838

Türk M.; Türker, M.; Ak, M.; Karaayak, B. & Kaya, T. (2004). Cyclosporiasis associated with diarrhoea in an immunocompetent patient in Turkey. *Journal of Medical Microbiology*, Vol.58, No.3, (March 2004), pp. 255-257, ISSN 0022-2615

Tuteja, A.K.; Taley, N.J.; Gelman,S.S.; Alder. S.C.; Thompson, C.; Tolman, K. & Hale, D.C. (2008). Development of functional diarrhea, constipation, irritable bowel syndrome, and dyspepsia during and after traveling outside the USA. *Digestive Diseases and Sciences*, Vol.53, No.1, (January 2008), pp. ; 271-276, ISSN 0163-2116

Tzipori, S. & Ward, H. (2002). Cryptosporidiosis: biology, pathogenesis and disease. *Microbes and Infection*, Vol.4, No.10, (August 2002), pp. 1047-1058, ISSN 1286-4579

Vassalos, C.M.; Spanakos, G.; Vassalou, E.; Papadopoulou, C. & Vakalis, N. (2010). Differences in clinical significance and morphologic features of *Blastocystis* sp. subtype 3. (2010). *American Journal of Clinical Pathology*, Vol.133, No.2, (February 2010), pp.251-258, ISSN 0002-9173

Vassalos, C.M.; Vakalis, N. & Papadopoulou, C. (2008). *Blastocystis* and its pathogenic potential: latest aspect. *Reviews in Medical Microbiology*, Vol.19, No.4, (October 2008), pp. 87-97, ISSN 0954-139X

Vassalos, C.M.; Vassalou, E.; Sofos, N. & Vakalis, N. Health Problems of Spiritual/Heritage Tourists and Christian "Hajji" Pilgrims Upon Returning from the Middle East. *CISTM12 Abstracts – Poster Presentations*, Poster No.06.14, Bosron, USA, (May 2011), p.58

Vassalou, E.; Vassalos, C. M.; Piperaki, E.-T. & Vakalis, N. (2010). To notice the unnoticed (Studying overlooked intestinal protozoa in Greece). "*Research in Progress 2010: Shorts Presentations and Posters*", The Royal Society of Tropical Medicine & Hygiene, London, UK, (December 2010), Poster No.24

Vollet, J.J.; Ericsson, C.D.; Gibson, G.; Pickering, L.K.; DuPont, H.L.; Kohl, S. & Conklin, R.H. (1979). Human rotavirus in an adult population with traveler's diarrhea and its relationship to the location of food consumption. *Journal of Medical Virology*, Vol.4, No.2, (1979), pp. 81-87. ISSN 0146-6615

Wagner, A. & Wiedermann, U. (2009). Travellers' diatthoea-pros and cons of different prophylactic measures. *Wiener klinische Wochenschrift*, Vol.121, Suppl.3, (October 2009), pp. 13-18, ISSN 0043-5325

Weedall, G.D. & Neil Hall, N. (2011). Evolutionary genomics of *Entamoeba*. *Research in Microbiology*, Vol.162, No.6, (July-August 2011), pp. 637-645. ISSN 0923-2508

Widdowson, M.A.; Cramer, E.H.; Hadley, L. & Bresee, J.S. (2002). Outbreaks of acute gastroenteritis on cruise ships and on land: identification of a predominant circulating strain of norovirus-United States, 2002. *Journal of Infectious Diseases*, Vol.190, No.1, (December 2004), pp. 27-36, ISSN 0022-1899

Williams, B.A. (2009). Unique physiology of host-parasite interactions in microsporidia infections. *Cellular Microbiology*, Vol.11, No.11, (November 2009), pp. 1551-1560, ISSN 1462-5814

Yates, J. (2005). Traveler's diarrhea. *American Family Physician*, Vol.71, No.11, (July 2005), pp. 2095-2100, 2107-2108,ISSN 0002-838X

Zimmer, S. M.; Schuetz A. N. & C. Franco-Paredes, C. (2007) . Efficacy of nitazoxanide for cyclosporiasis in patients with sulfa allergy. *Clinical Infectious Diseases*, Vol.44, No.3, (February 2007), pp. 466-467, ISSN 1058-4838

Current Concepts in Colonic Disorders

Edited by Dr. Godfrey Lule

The 21st Century has seen a resurgence of research of the gastrointestinal tract, especially since it was established that it plays a central role as an immune system organ and consequentially has a huge impact on causation, impact and transmission of most human ailments. New diseases such as the Acquired Immunodeficiency Syndrome, hepatitis and tumours of the gastrointestinal tract have emerged and they are currently subjects of intensive research and topics of scientific papers published worldwide. Old diseases like diarrhea have become extremely complex to diagnose with new and old pathogens, drugs, tumours and malabsorptive disorders accounting for the confusion. This book has set out algorithms on how to approach such conditions in a systematic way both to reach a diagnosis and to make patient management cheaper and more efficient. "Current Concepts in Colonic Disorders" attempts to put all the new information into proper perspective with emphasis on aetiopathogenesis and providing rational approach to management of various old and new diseases. As the book editor, I have found this first edition extremely interesting and easy to understand. Comments on how to improve the content and manner of presentation for future editions are extremely welcome.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

INTECH
open science | open minds